<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antiseptic solutions for skin preparation during central catheter insertion in neonates - Muhd Helmi, MA - 2023 | Cochrane Library</title> <meta content="Antiseptic solutions for skin preparation during central catheter insertion in neonates - Muhd Helmi, MA - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013841.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antiseptic solutions for skin preparation during central catheter insertion in neonates - Muhd Helmi, MA - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013841.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013841.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Antiseptic solutions for skin preparation during central catheter insertion in neonates" name="citation_title"/> <meta content="Muhd Alwi Muhd Helmi" name="citation_author"/> <meta content="Kulliyyah of Medicine, International Islamic University Malaysia" name="citation_author_institution"/> <meta content="muhdalwi@gmail.com" name="citation_author_email"/> <meta content="Nai Ming Lai" name="citation_author"/> <meta content="Taylor's University" name="citation_author_institution"/> <meta content="Hans Van Rostenberghe" name="citation_author"/> <meta content="Universiti Sains Malaysia" name="citation_author_institution"/> <meta content="Izzudeen Ayub" name="citation_author"/> <meta content="Hospital Pengajar Universiti Sultan Zainal Abidin" name="citation_author_institution"/> <meta content="Emie Mading" name="citation_author"/> <meta content="University Malaysia Sabah (UMS)" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD013841.pub2" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/05/04" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013841.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013841.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013841.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Anti-Infective Agents, Local [therapeutic use]; *Burns, Chemical [drug therapy, etiology]; *Central Venous Catheters [adverse effects]; Chlorhexidine [adverse effects]; *Sepsis [drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013841.pub2&amp;doi=10.1002/14651858.CD013841.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013841.pub2&amp;doi=10.1002/14651858.CD013841.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013841.pub2&amp;doi=10.1002/14651858.CD013841.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013841.pub2&amp;doi=10.1002/14651858.CD013841.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013841.pub2&amp;doi=10.1002/14651858.CD013841.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013841.pub2&amp;doi=10.1002/14651858.CD013841.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013841.pub2&amp;doi=10.1002/14651858.CD013841.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013841.pub2&amp;doi=10.1002/14651858.CD013841.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013841.pub2&amp;doi=10.1002/14651858.CD013841.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013841.pub2&amp;doi=10.1002/14651858.CD013841.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013841.pub2&amp;doi=10.1002/14651858.CD013841.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013841.pub2&amp;doi=10.1002/14651858.CD013841.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013841.pub2&amp;doi=10.1002/14651858.CD013841.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013841.pub2&amp;doi=10.1002/14651858.CD013841.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013841.pub2&amp;doi=10.1002/14651858.CD013841.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013841.pub2&amp;doi=10.1002/14651858.CD013841.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013841.pub2&amp;doi=10.1002/14651858.CD013841.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013841.pub2&amp;doi=10.1002/14651858.CD013841.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013841.pub2&amp;doi=10.1002/14651858.CD013841.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013841.pub2&amp;doi=10.1002/14651858.CD013841.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013841.pub2&amp;doi=10.1002/14651858.CD013841.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013841.pub2&amp;doi=10.1002/14651858.CD013841.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013841.pub2&amp;doi=10.1002/14651858.CD013841.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="p32VIvbS";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013841\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013841\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013841\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013841\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ko","th","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013841.pub2",title:"Antiseptic solutions for skin preparation during central catheter insertion in neonates",firstPublishedDate:"May 4, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Neonatal Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=p32VIvbS&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013841.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013841.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013841.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013841.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013841.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013841.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013841.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013841.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013841.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013841.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3866 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013841.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013841.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013841.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013841.pub2/full#CD013841-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013841.pub2/full#CD013841-sec-0096"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013841.pub2/full#CD013841-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013841.pub2/full#CD013841-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013841.pub2/full#CD013841-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013841.pub2/full#CD013841-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013841.pub2/full#CD013841-sec-0041"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013841.pub2/full#CD013841-sec-0090"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013841.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013841.pub2/appendices#CD013841-sec-0101"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013841.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013841.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/supinfo/CD013841-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/supinfo/CD013841-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013841.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013841.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013841.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013841.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013841.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013841.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antiseptic solutions for skin preparation during central catheter insertion in neonates</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013841.pub2/information#CD013841-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Muhd Alwi Muhd Helmi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013841.pub2/information#CD013841-cr-0005">Nai Ming Lai</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013841.pub2/information#CD013841-cr-0006">Hans Van Rostenberghe</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013841.pub2/information#CD013841-cr-0007">Izzudeen Ayub</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013841.pub2/information#CD013841-cr-0008">Emie Mading</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/information/en#CD013841-sec-0113">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 04 May 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013841.pub2">https://doi.org/10.1002/14651858.CD013841.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013841-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013841-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013841-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013841-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013841-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013841-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD013841-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013841-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013841-abs-0001" lang="en"> <section id="CD013841-sec-0001"> <h3 class="title" id="CD013841-sec-0001">Background</h3> <p>Central venous catheters (CVC) are associated with potentially dangerous complications such as thromboses, pericardial effusions, extravasation, and infections in neonates. Indwelling catheters are amongst the main risk factors for nosocomial infections. The use of skin antiseptics during the preparation for central catheter insertion may prevent catheter‐related bloodstream infections (CRBSI) and central line‐associated bloodstream infections (CLABSI). However, it is still not clear which antiseptic solution is the best to prevent infection with minimal side effects. </p> </section> <section id="CD013841-sec-0002"> <h3 class="title" id="CD013841-sec-0002">Objectives</h3> <p>To systematically evaluate the safety and efficacy of different antiseptic solutions in preventing CRBSI and other related outcomes in neonates with CVC. </p> </section> <section id="CD013841-sec-0003"> <h3 class="title" id="CD013841-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, Embase, and trial registries up to 22 April 2022. We checked reference lists of included trials and systematic reviews that related to the intervention or population examined in this Cochrane Review.  </p> </section> <section id="CD013841-sec-0004"> <h3 class="title" id="CD013841-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) or cluster‐RCTs were eligible for inclusion in this review if they were performed in the neonatal intensive care unit (NICU), and were comparing any antiseptic solution (single or in combination) against any other type of antiseptic solution or no antiseptic solution or placebo in preparation for central catheter insertion. We excluded cross‐over trials and quasi‐RCTs. </p> </section> <section id="CD013841-sec-0005"> <h3 class="title" id="CD013841-sec-0005">Data collection and analysis</h3> <p>We used the standard methods from Cochrane Neonatal. We used the GRADE approach to assess the certainty of the evidence. </p> </section> <section id="CD013841-sec-0006"> <h3 class="title" id="CD013841-sec-0006">Main results</h3> <p>We included three trials that had two different comparisons: 2% chlorhexidine in 70% isopropyl alcohol (CHG‐IPA) versus 10% povidone‐iodine (PI) (two trials); and CHG‐IPA versus 2% chlorhexidine in aqueous solution (CHG‐A) (one trial). A total of 466 neonates from level III NICUs were evaluated. All included trials were at high risk of bias. The certainty of the evidence for the primary and some important secondary outcomes ranged from very low to moderate. There were no included trials that compared antiseptic skin solutions with no antiseptic solution or placebo. </p> <p><b>CHG‐IPA versus 10% PI</b> </p> <p>Compared to PI, CHG‐IPA may result in little to no difference in CRBSI (risk ratio (RR) 1.32, 95% confidence interval (CI) 0.53 to 3.25; risk difference (RD) 0.01, 95% CI −0.03 to 0.06; 352 infants, 2 trials, low‐certainty evidence) and all‐cause mortality (RR 0.88, 95% CI 0.46 to 1.68; RD −0.01, 95% CI −0.08 to 0.06; 304 infants, 1 trial, low‐certainty evidence). The evidence is very uncertain about the effect of CHG‐IPA on CLABSI (RR 1.00, 95% CI 0.07 to 15.08; RD 0.00, 95% CI −0.11 to 0.11; 48 infants, 1 trial; very low‐certainty evidence) and chemical burns (RR 1.04, 95% CI 0.24 to 4.48; RD 0.00, 95% CI −0.03 to 0.03; 352 infants, 2 trials, very low‐certainty evidence), compared to PI. Based on a single trial, infants receiving CHG‐IPA appeared less likely to develop thyroid dysfunction compared to PI (RR 0.05, 95% CI 0.00 to 0.85; RD −0.06, 95% CI −0.10 to −0.02; number needed to treat for an additional harmful outcome (NNTH) 17, 95% CI 10 to 50; 304 infants). Neither of the two included trials assessed the outcome of premature central line removal or the proportion of infants or catheters with exit‐site infection. </p> <p><b>CHG‐IPA versus CHG‐A</b> </p> <p>The evidence suggests CHG‐IPA may result in little to no difference in the rate of proven CRBSI when applied on the skin of neonates prior to central line insertion (RR 0.80, 95% CI 0.34 to 1.87; RD −0.05, 95% CI −0.22 to 0.13; 106 infants, 1 trial, low‐certainty evidence) and CLABSI (RR 1.14, 95% CI 0.34 to 3.84; RD 0.02, 95% CI −0.12 to 0.15; 106 infants, 1 trial, low‐certainty evidence), compared to CHG‐A. Compared to CHG‐A, CHG‐IPA probably results in little to no difference in premature catheter removal (RR 0.91, 95% CI 0.26 to 3.19; RD −0.01, 95% CI −0.15 to 0.13; 106 infants, 1 trial, moderate‐certainty evidence) and chemical burns (RR 0.98, 95% CI 0.47 to 2.03; RD −0.01, 95% CI −0.20 to 0.18; 114 infants, 1 trial, moderate‐certainty evidence). No trial assessed the outcome of all‐cause mortality and the proportion of infants or catheters with exit‐site infection. </p> </section> <section id="CD013841-sec-0007"> <h3 class="title" id="CD013841-sec-0007">Authors' conclusions</h3> <p>Based on current evidence, compared to PI, CHG‐IPA may result in little to no difference in CRBSI and mortality. The evidence is very uncertain about the effect of CHG‐IPA on CLABSI and chemical burns. One trial showed a statistically significant increase in thyroid dysfunction with the use of PI compared to CHG‐IPA. </p> <p>The evidence suggests CHG‐IPA may result in little to no difference in the rate of proven CRBSI and CLABSI when applied on the skin of neonates prior to central line insertion. Compared to CHG‐A, CHG‐IPA probably results in little to no difference in chemical burns and premature catheter removal. </p> <p>Further trials that compare different antiseptic solutions are required, especially in low‐ and middle‐income countries, before stronger conclusions can be made.  </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013841-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013841-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013841-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013841-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013841-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013841-abs-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD013841-abs-0011">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013841-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013841-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/th#CD013841-abs-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013841-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013841-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013841-abs-0002" lang="en"> <h3>Chlorhexidine or other antiseptic solutions: which works better to prevent infection in newborns with central lines? </h3> <p><b>Key messages:</b> </p> <p>    • Due to a lack of robust evidence, the benefits and risks of chlorhexidine in alcohol compared to povidone‐iodine (PI) as antiseptic solution for central line insertion in newborns are unclear. </p> <p>    • The use of povidone in premature infants may reduce the level of thyroid hormone, which is an essential hormone for growth and development. </p> <p>    • The limited number of studies and the lack of studies from low‐ and middle‐income countries reduce our confidence in the certainty and applicability of the evidence. </p> <p><b>What is a central catheter?</b> </p> <p>Babies who require intensive care may need a special line, known as a central line, inserted into their blood vessels. Central lines are needed for a variety of reasons, including giving medications and nutrients. These central lines are important but can lead to various complications.  </p> <p><b>What are catheter‐related blood stream infection (CRBSI) and central line‐associated bloodstream infection (CLABSI)?</b> </p> <p>Serious infections are amongst the most frequent complications of central line insertion. Infection that originated or possibly originated from the central line is called CRBSI and CLABSI respectively. These infections are potentially preventable by using antiseptic solutions on the skin before inserting the lines. </p> <p><b>What did we want to find out?</b> </p> <p>We were interested to know which antiseptic solution is best in:<br/>    • preventing CRBSI/CLABSI; </p> <p>    • reducing the rate of infection in the blood;</p> <p>    • preventing the growth of germs inside the catheters.</p> <p>We were also interested to know if the use of these solutions increased the risk of chemical irritation on the skin of small infants or caused other adverse effects. </p> <p><b>What did we do?</b> </p> <p>We searched for trials that compared: </p> <p>    • different types of antiseptic solutions; or </p> <p>    • different concentrations of the same antiseptic solution.</p> <p>We compared and summarised their results, and rated our confidence in the evidence, based on factors such as study methods and sizes. </p> <p><b>What did we find?</b> </p> <p>We found three trials: one from the USA, one from the UK, and one from Ireland. These trials involved 466 babies and were conducted in neonatal intensive care units. Two trials compared 10% PI versus 2% chlorhexidine in 70% isopropyl alcohol. The third trial compared two different preparations of chlorhexidine: an alcohol‐based solution, and a water‐based solution. All the trials involved premature babies born between 26 and 35 weeks of pregnancy and had a birthweight between 1000 g and 2000 g. None of the studies were funded by pharmaceutical companies.  </p> <p><b>Main results</b> </p> <p>In trials comparing 2% chlorhexidine in 70% alcohol (CHG‐IPA) and PI:<br/>    • Compared to PI, the use of CHG‐IPA may result in little to no difference in CRBSI (2 trials, 352 infants) and death (1 trial, 304 infants). It is unclear whether CHG‐IPA reduces skin burns and CLABSI (2 trials, 352 infants).<br/>    • The use of 10% PI could disturb the production of thyroid hormone (1 trial, 304 infants).  </p> <p>Compared to water‐based chlorhexidine, alcohol‐based chlorhexidine may result in little to no difference in the rate of proven CRBSI and CLABSI and probably results in little to no difference in skin irritation (1 trial, 114 infants). </p> <p><b>What are the limitations of the evidence?</b> </p> <p>Compared to PI, we have little confidence that chlorhexidine is better at preventing CRBSI, CLABSI, or death, and we are not confident in the evidence that chlorhexidine is better than PI for other outcomes. The studies included were small, and the people involved in the studies were aware of the solution received by the infants, which may have influenced the outcomes.  </p> <p><b>How up to date is this evidence?</b> </p> <p>The evidence is up‐to‐date to 22 April 2022.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013841-sec-0096" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013841-sec-0096"></div> <h3 class="title" id="CD013841-sec-0097">Implications for practice</h3> <section id="CD013841-sec-0097"> <p>In conclusion, compared to PI, CHG‐IPA may result in little to no difference in CRBSI and mortality. CHG‐IPA may have little to no effect on CLABSI and chemical burns, but the evidence is very uncertain. One trial showed a statistically significant increase in thyroid dysfunction with the use of PI compared to CHG‐IPA.  </p> <p>Compared to CHG‐A, the evidence suggests CHG‐IPA may result in little to no difference in the rate of proven CRBSI and CLABSI when applied on the skin of neonates prior to central line insertion and probably results in little to no difference in chemical burns and premature central line removal. </p> <p>Further trials that compare different antiseptic solutions, especially in low‐ and middle‐income countries, are required before stronger conclusions can be made.  </p> </section> <h3 class="title" id="CD013841-sec-0098">Implications for research</h3> <section id="CD013841-sec-0098"> <p>Further RCTs are needed comparing different antiseptic solutions for skin preparation during CVC insertion in neonates. This Cochrane Review found several issues in the included trials, which should be considered by researchers undertaking future trials.  </p> <p>First, blinding of outcome assessor was not achieved in trials that compared antiseptic solutions with different physical properties, e.g. chlorhexidine versus PI. Despite the challenges in blinding the personnel, effort should be made to blind the assessors of outcomes, especially the subjective ones. Blinding could be made possible by appointing different assessors for each outcome or using solutions with a similar appearance.  </p> <p>Secondly, all the trials were conducted in tertiary‐level NICUs in high‐income countries. Advance in the standard care and other antisepsis measures practised in the NICUs may influence the rate of outcomes such as CRBSI and sepsis. The issue with multiple applications of antiseptic solution or the change of dressing material has to be considered when designing trials using antiseptic solutions. For instance, one included trial changed the dressing and reapplied the designated antiseptic solution weekly, another trial changed CVC dressing on per needed basis, while the other trial did not report the standard antisepsis measures in its protocol. Besides that, the included trials applied different inclusion criteria based on gestational ages and body weight.  </p> <p>There is also an issue with the entry criteria of the participants. One trial selected only neonates of at least seven days of age, while the other two trials recruited newborns.  </p> <p>Finally, future research should include critical outcomes, such as exit site infection, alongside catheter‐specific outcomes, such as premature removal of catheters, and report participant‐level data and catheter‐level data. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013841-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013841-sec-0008"></div> <div class="table" id="CD013841-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">CHG‐IPA versus PI for skin preparation during central‐catheter insertion in neonates</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CHG‐IPA versus PI for skin preparation during central‐catheter insertion in neonates</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> neonates that require central line </p> <p><b>Setting:</b> tertiary‐level NICUs in the USA and Ireland </p> <p><b>Intervention:</b> CHG‐IPA </p> <p><b>Comparison:</b> PI </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with PI</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with CHG‐IPA</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proven catheter‐related bloodstream infection (CRBSI) expressed by the authors of the individual trials as absolute rates assessed with: number of infants </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>44 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 1000</b><br/>(24 to 144) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.32</b><br/>(0.53 to 3.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>352<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>LOW <sup>a, b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Central line‐associated bloodstream infection (CLABSI) expressed using absolute rates of infants </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>42 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>42 per 1000</b> </p> <p>(3 to 628)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b> </p> <p>(0.07 to 15.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>VERY LOW <sup>c, d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The proportion of infants or catheters with exit‐site infection, either microbiologically or clinically documented </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trial assessed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Premature central line removal, defined as number of central venous catheters (CVCs) removed in the trial as deemed by the author as the source of infection </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trial assessed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chemical burns or contact dermatitis, measured using a scoring system or by clinical judgement as described by the trial author during or after the application of antiseptic solutions (dermatitis) assessed with: number of infants </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 per 1000</b><br/>(4 to 75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.04</b><br/>(0.24 to 4.48) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>352<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>VERY LOW <sup>c, e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality throughout the hospital admission of the participant (mortality) assessed with: number of infants </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>115 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>102 per 1000</b><br/>(53 to 194) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.88</b><br/>(0.46 to 1.68) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>304<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>LOW<sup>a, f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>CHG‐IPA:</b> 2% chlorhexidine in 70% isopropyl alcohol; <b>CRBSI</b> : catheter‐related bloodstream infection; <b>CVCs</b> : central venous catheters; <b>NICUs:</b> neonatal intensive care units; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Both trials had a high risk of performance bias. Certainty of evidence was downgraded by one level for serious limitation.<br/><sup>b</sup>The risk of CRBSI can possibly be halved with the use of CHG‐IPA. However, the increase in risk by 3.25 times was plausible. Certainty of evidence was downgraded by one level for imprecision.<br/><sup>c</sup>The included had a high risk of performance and detection biases. With very serious limitations, the certainty of evidence was downgraded by two levels.<br/><sup>d</sup>The risk of CLABSI with the use of CHG‐IPA or PI is the same. Certainty of evidence was downgraded by one level for imprecision.<br/><sup>e</sup>The risk of chemical burns reduced by 0.76 times with the use of CHG‐IPA but with a significant possibility of an increase in the risk of chemical burns by 4.5 times. Certainty of evidence was downgraded by one level for imprecision.<br/><sup>f</sup>The risk of death reduced by half with the use of CHG‐IPA. However, 1.7 times increase risk of death was plausible. Certainty of evidence was downgraded by one level for imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013841-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">CHG‐IPA versus CHG‐A for skin preparation during central‐catheter insertion in neonates</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CHG‐IPA versus CHG‐A for skin preparation during central‐catheter insertion in neonates</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> neonates that require central line </p> <p><b>Setting:</b> tertiary‐level NICUs in the UK </p> <p><b>Intervention:</b> CHG‐IPA </p> <p><b>Comparison:</b> CHG‐A </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with CHG‐A</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with CHG‐IPA</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proven catheter‐related bloodstream infection (CRBSI) expressed by the authors of the individual trial as absolute rates assessed with: number of infants </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>222 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>178 per 1000</b><br/>(416 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.80</b><br/>(0.34 to 1.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>LOW <sup>a, b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Central‐line associated bloodstream infection (CLABSI) expressed by the authors of the individual trial as absolute rates assessed with: number of infants </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>127 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>144 per 1000</b><br/>(43 to 486) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.14</b><br/>(0.34 to 3.84) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>LOW<sup>a, c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The proportion of infants or catheters with exit‐site infection, either microbiologically or clinically documented </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trial assessed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Premature central line removal, defined as number of central venous catheters (CVC) removed in the trial as deemed by the author as the source of infection (premature central line removal) assessed with: number of infants </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>101 per 1000</b><br/>(29 to 354) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.91</b><br/>(0.26 to 3.19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁⨁◯<br/>MODERATE<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chemical burns or contact dermatitis, measured using a scoring system or by clinical judgement as described by the trial author during or after the application of antiseptic solutions (dermatitis) assessed with: number of infants </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>259 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>254 per 1000</b><br/>(122 to 526) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.98</b><br/>(0.47 to 2.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁⨁◯<br/>MODERATE<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality throughout the hospital admission of the participant</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trial assessed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CHG‐IPA:</b> 2% chlorhexidine in 70% isopropyl alcohol; <b>CHG‐A:</b> 2% chlorhexidine in aqueous solution; <b>CI:</b> confidence interval; <b>CRBSI:</b> catheter‐related bloodstream infection; <b>CVCs</b> : central venous catheters; <b>NICUs:</b> neonatal intensive care units; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>There was a high risk of attrition bias. The missing data were larger than the difference between events in the intervention and control groups. Certainty of evidence was downgraded by one level for serious limitation.<br/><sup>b</sup>There was a possible reduction in the risk of CRBSI by one‐third with the use of CHG‐IPA. However, the increase in risk by 1.9 times was plausible. Certainty of evidence was downgraded by one level for imprecision.<br/><sup>c</sup>There is an almost 0.7 times possible reduction in the risk of CLABSI with the use of CHG‐IPA. However, the increase in risk by 3.8 times is plausible. Certainty of evidence was downgraded by one level for imprecision.<br/><sup>d</sup>The risk of premature central catheter removal was reduced by 0.26 times with the use of CHG‐IPA but with a significant possibility of an increase in the risk of premature catheter removal by three times. Certainty of evidence was downgraded by one level for imprecision.<br/><sup>e</sup>The risk of chemical burns was reduced by half with the use of CHG‐IPA but with a significant possibility of an increase in the risk of chemical burns by two times. Certainty of evidence was downgraded by one level for imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013841-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013841-sec-0009"></div> <section id="CD013841-sec-0010"> <h3 class="title" id="CD013841-sec-0010">Description of the condition</h3> <p>Central venous catheters (CVCs) are flexible, long catheters inserted through the skin, or occasionally via a surgical incision, into the right atrium or one of the great vessels such as the vena cava, subclavian, femoral, common iliac, or umbilical vein (<a href="./references#CD013841-bbs2-0016" title="Centers for Disease Control and Prevention (CDC). Bloodstream infection event (central line-associated bloodstream infection and non-central line associated bloodstream infection). January 2023. www.cdc.gov/nhsn/pdfs/pscmanual/4psc_clabscurrent.pdf (accessed 19 January 2023).">CDC 2023</a>; <a href="./references#CD013841-bbs2-0022" title="DongaraAR , PatelDV , NimbalkarSM , PotanaN , NimbalkarAS . Umbilical venous catheter versus peripherally inserted central catheter in neonates: a randomized controlled trial. Journal of Tropical Pediatrics2017;63(5):374-9. [DOI: 10.1093/tropej/fmw099] [PMID: 28077611]">Dongara 2017</a>; <a href="./references#CD013841-bbs2-0056" title="SmithRN , NolanJP . Central venous catheters. BMJ2013;347:f6570. [DOI: 10.1136/bmj.f6570] [PMID: 24217269]">Smith 2013</a>). CVCs are used to administer fluids (e.g. parenteral nutrition, blood products, or medications e.g. inotrope) and to monitor the haemodynamic status. In 1994, the estimated total number of central catheters inserted in adult and neonatal intensive care units (NICUs) in the UK was 200,000, and a rise in the number of insertions was expected (<a href="./references#CD013841-bbs2-0056" title="SmithRN , NolanJP . Central venous catheters. BMJ2013;347:f6570. [DOI: 10.1136/bmj.f6570] [PMID: 24217269]">Smith 2013</a>). In the USA, at least 30% of all infants admitted to NICU had CVCs inserted at some stage during their NICU stay (<a href="./references#CD013841-bbs2-0057" title="SoaresBN , PissarraS , Rouxinol-DiasAL , CostaS , GuimarãesH . Complications of central lines in neonates admitted to a level III Neonatal Intensive Care Unit. Journal of Maternal-Fetal &amp; Neonatal Medicine2018;31(20):2770-6. [DOI: 10.1080/14767058.2017.1355902] [PMID: 28707497]">Soares 2018</a>). CVCs are usually inserted into either peripheral veins or large central veins such as the umbilical veins, or the subclavian and brachio‐cephalic veins as in the case of centrally inserted central line. </p> <p>The incidence of serious complications of CVCs in neonates, such as thrombosis, infection, pericardial effusion, extravasation, and catheter ruptures, ranges from 2.9% to 23.6% (<a href="./references#CD013841-bbs2-0008" title="ArntsIJ , BullensLM , GroenewoudJM , LiemKD . Comparison of complication rates between umbilical and peripherally inserted central venous catheters in newborns. Journal of Obstetric, Gynecologic, and Neonatal Nursing2014;43(2):205-15. [DOI: 10.1111/1552-6909.12278] [PMID: 24502854]">Arnts 2014</a>; <a href="./references#CD013841-bbs2-0047" title="OhkiY , MaruyamaK , HarigayaA , KohnoM , ArakawaH . Complications of peripherally inserted central venous catheter in Japanese neonatal intensive care units. Pediatrics International2013;55(2):185-9. [DOI: 10.1111/ped.12033] [PMID: 23253251]">Ohki 2013</a>; <a href="./references#CD013841-bbs2-0057" title="SoaresBN , PissarraS , Rouxinol-DiasAL , CostaS , GuimarãesH . Complications of central lines in neonates admitted to a level III Neonatal Intensive Care Unit. Journal of Maternal-Fetal &amp; Neonatal Medicine2018;31(20):2770-6. [DOI: 10.1080/14767058.2017.1355902] [PMID: 28707497]">Soares 2018</a>). Catheter‐related infections, which include catheter‐related bloodstream infections (CRBSI) and central line‐associated bloodstream infections (CLABSI), are the most common cause of late‐onset sepsis, especially in preterm infants (<a href="./references#CD013841-bbs2-0032" title="KaplanHC , LannonC , WalshMC , DonovanEF , Ohio Perinatal Quality Collaborative. Ohio statewide quality-improvement collaborative to reduce late-onset sepsis in preterm infants. Pediatrics2011;127(3):427-35. [DOI: 10.1542/peds.2010-2141] [PMID: 21339274]">Kaplan 2011</a>). The Centers for Disease Control and Prevention (CDC) defines CRBSI as the presence of systemic signs and symptoms of sepsis at the time of catheter removal with the catheter site identified as the source of infection confirmed by positive culture of the same organism both in the blood and from a catheter segment (<a href="./references#CD013841-bbs2-0015" title="O’GradyNP , AlexanderM , BurnsLA , DellingerP , GarlandJ , HeardS , et al, the Healthcare Infection Control Practices Advisory Committee (HICPAC). Guidelines for the prevention of intravascular catheter-related infections, 2011. www.cdc.gov/infectioncontrol/pdf/guidelines/bsi-guidelines-H.pdf (accessed prior to 15 December 2020).">CDC 2011</a>). CRBSI differs from CLABSI because the diagnosis of CLABSI does not require catheter segment culture positivity and therefore has a much broader definition (<a href="./references#CD013841-bbs2-0015" title="O’GradyNP , AlexanderM , BurnsLA , DellingerP , GarlandJ , HeardS , et al, the Healthcare Infection Control Practices Advisory Committee (HICPAC). Guidelines for the prevention of intravascular catheter-related infections, 2011. www.cdc.gov/infectioncontrol/pdf/guidelines/bsi-guidelines-H.pdf (accessed prior to 15 December 2020).">CDC 2011</a>; <a href="./references#CD013841-bbs2-0038" title="LissauerME , LeekhaS , PreasMA , ThomKA , JohnsonSB . Risk factors for central line-associated bloodstream infections in the era of best practice. Journal of Trauma and Acute Care Surgery2012;72(5):1174-80. [DOI: 10.1097/TA.0b013e31824d1085] [PMID: 22673242]">Lissauer 2012</a>). CLABSI is diagnosed when an infant fulfilled the criteria for a primary laboratory‐confirmed bloodstream infection with an identification of an eligible organism and the presence of a central line on the day of the event or in the last 24 hours (<a href="./references#CD013841-bbs2-0016" title="Centers for Disease Control and Prevention (CDC). Bloodstream infection event (central line-associated bloodstream infection and non-central line associated bloodstream infection). January 2023. www.cdc.gov/nhsn/pdfs/pscmanual/4psc_clabscurrent.pdf (accessed 19 January 2023).">CDC 2023</a>). </p> <p>Globally, CRBSI causes a significant economic burden to patients and healthcare systems. The cost ranges as low as USD 5000 per year for patients in low‐ and middle‐income countries, up to USD 70,000 per year for patients in the USA (<a href="./references#CD013841-bbs2-0014" title="CaiY , ZhuM , SunW , CaoX , WuH . Study on the cost attributable to central venous catheter-related bloodstream infection and its influencing factors in a tertiary hospital in China. Health and quality of life outcomes. Health and Quality of Life Outcomes2018;16(1):198. [DOI: doi.org/10.1186/s12955-018-1027-3]">Cai 2018</a>). In neonates, the rate of CRBSI ranges between 2% and 23.5% with a higher incidence rate in low‐ and middle‐income countries (<a href="./references#CD013841-bbs2-0009" title="BadrRI , HammadE , SalamaMF , ShoumanB , Abdel-HadyH , NasefN . Central venous catheter-related blood stream infections in neonatal care unit. International Journal of Infection Control2013;9(3):1-8. [DOI: 10.3396/ijic.v9i3.11249]">Badr 2013</a>; <a href="./references#CD013841-bbs2-0023" title="FerreiraJ , CamargosPA , RosadoV , MourãoPH , RomanelliRM . Risk factors for central venous catheter-related bloodstream infection in neonates. American Journal of Infection Control2020;48(9):1102-3. [DOI: 10.1016/j.ajic.2019.12.004]">Ferreira 2020</a>; <a href="./references#CD013841-bbs2-0059" title="TomarRS , GuptaAK , KhanID . Incidence of catheter-related bloodstream infections after removal of peripherally inserted central catheters in preterm neonates. International Journal of Contemporary Pediatrics2019;7(2):282-6. [DOI: 10.18203/2349-3291.ijcp20200018] [PISSN: 2349-3283]">Tomar 2019</a>). CRBSI cause significant morbidity and mortality to newborns in intensive care units, particularly to extremely preterm infants. A Swiss cohort study found that sepsis in extremely preterm neonates increased the risk of neurodevelopmental impairment and cerebral palsy compared to infants without sepsis, with an odds ratio of 1.85 and 2.90, respectively (<a href="./references#CD013841-bbs2-0053" title="SchlapbachLJ , AebischerM , AdamsM , NatalucciG , BonhoefferJ , LatzinP , et al. Impact of sepsis on neurodevelopmental outcome in a Swiss National Cohort of extremely premature infants. Pediatrics2011;128(2):e348-57. [DOI: 10.1542/peds.2010-3338] [PMID: 21768312]">Schlapbach 2011</a>). Factors that can affect the rate of CRBSI include the type of catheter, lower birth weight, increasing duration of catheter‐dwelling time, a lower APGAR score at five minutes, and femoral vein insertion (<a href="./references#CD013841-bbs2-0021" title="deBritoCS , deBritoDV , AbdallahVO , Gontijo FilhoPP . Occurrence of bloodstream infection with different types of central vascular catheter in critically neonates. Journal of Infection2010;60(2):128-32. [DOI: 10.1016/j.jinf.2009.11.007] [PMID: 19944717]">de Brito 2010</a>; <a href="./references#CD013841-bbs2-0023" title="FerreiraJ , CamargosPA , RosadoV , MourãoPH , RomanelliRM . Risk factors for central venous catheter-related bloodstream infection in neonates. American Journal of Infection Control2020;48(9):1102-3. [DOI: 10.1016/j.ajic.2019.12.004]">Ferreira 2020</a>; <a href="./references#CD013841-bbs2-0028" title="HuY , LingY , YeY , ZhangL , XiaX , JiangQ , et al. Analysis of risk factors of PICC-related bloodstream infection in newborns: implications for nursing care. European Journal of Medical Research2021;26(1):80. [DOI: 10.1186/s40001-021-00546-2]">Hu 2021</a>). Even though the culture of umbilical catheter tips yields a significantly higher rate of positive culture than the culture of the peripherally inserted central catheter (PICC) tip, when comparing the rate of CRBSI between PICC and umbilical catheter, use of PICC was associated with a significantly higher rate of CRBSI in a few observational studies; this finding is most likely due to PICC's longer in‐dwelling time than the umbilical catheters (<a href="./references#CD013841-bbs2-0021" title="deBritoCS , deBritoDV , AbdallahVO , Gontijo FilhoPP . Occurrence of bloodstream infection with different types of central vascular catheter in critically neonates. Journal of Infection2010;60(2):128-32. [DOI: 10.1016/j.jinf.2009.11.007] [PMID: 19944717]">de Brito 2010</a>; <a href="./references#CD013841-bbs2-0023" title="FerreiraJ , CamargosPA , RosadoV , MourãoPH , RomanelliRM . Risk factors for central venous catheter-related bloodstream infection in neonates. American Journal of Infection Control2020;48(9):1102-3. [DOI: 10.1016/j.ajic.2019.12.004]">Ferreira 2020</a>; <a href="./references#CD013841-bbs2-0034" title="KonstantinidiA , SokouR , PanagiotounakouP , LampridouM , ParastatidouS , TsantilaK , et al. Umbilical venous catheters and peripherally inserted central catheters: are they equally safe in VLBW infants? A non-randomized single center study. Medicina2019;55(8):442. [DOI: 10.3390/medicina55080442] [PMID: 31390790]">Konstantinidi 2019</a>). In the past, gram‐positive cocci were the most common organism that caused CRBSI. However, with the implementation of a stricter hand hygiene policy and infection control measures, and the use of prophylaxis antifungal therapy, gram‐negative bacteria became more common causes of CRBSI (<a href="./references#CD013841-bbs2-0028" title="HuY , LingY , YeY , ZhangL , XiaX , JiangQ , et al. Analysis of risk factors of PICC-related bloodstream infection in newborns: implications for nursing care. European Journal of Medical Research2021;26(1):80. [DOI: 10.1186/s40001-021-00546-2]">Hu 2021</a>). </p> <p>Multiple measures can be taken during the insertion and maintenance of a CVC in order to prevent CRBSI. For instance, the use of central line care bundle from the point of insertion until the removal and antibiotic lock therapy have been found to effectively reduce the rate of central line‐associated sepsis (<a href="./references#CD013841-bbs2-0037" title="LiangH , ZhangL , GuoX , SunL . Vancomycin-lock therapy for prevention of catheter-related bloodstream infection in very low body weight infants. BMC Pediatrics2021;21:3. [DOI: 10.1186/s12887-020-02482-2]">Liang 2021</a>; <a href="./references#CD013841-bbs2-0061" title="WangW , ZhaoC , JiQ , LiuY , ShenG , WeiL . Prevention of peripherally inserted central line-associated blood stream infections in very low-birth-weight infants by using a central line bundle guideline with a standard checklist: a case control study. BMC Pediatrics2015;15:69. [DOI: doi.org/10.1186/s12887-015-0383-y]">Wang 2015</a>). Included in the bundles are good hand hygiene, the use of antiseptic or antimicrobial dressings, antibiotic lock therapy, antibiotic‐impregnated catheters, prophylactic systemic antibiotics, and appropriate antiseptic solutions for skin preparation (<a href="./references#CD013841-bbs2-0043" title="MobleyRE , BizzarroMJ . Central line-associated bloodstream infections in the NICU: successes and controversies in the quest for zero. Seminars in Perinatology2017;41(3):166-74. [DOI: 10.1053/j.semperi.2017.03.006] [PMID: 28411947]">Mobley 2017</a>). In a previous Cochrane Review, the use of antibiotic‐impregnated dressing was found to reduce catheter colonisation significantly, but did not affect the rate of CRBSI (<a href="./references#CD013841-bbs2-0035" title="LaiNM , TaylorJE , TanK , ChooYM , Ahmad KamarA , MuhamadNA . Antimicrobial dressings for the prevention of catheter-related infections in newborn infants with central venous catheters. Cochrane Database of Systematic Reviews2016, Issue 3. Art. No: CD011082. [DOI: 10.1002/14651858.CD011082.pub2] [PMID: 27007217]">Lai 2016</a>), even though the use of antibiotic‐impregnated catheters significantly reduced the rate of CRBSI in preterm infants in a single randomised controlled trial (RCT) (<a href="./references#CD013841-bbs2-0013" title="BertiniG , EliaS , CeciariniF , DaniC . Reduction of catheter-related bloodstream infections in preterm infants by the use of catheters with the AgION antimicrobial system. Early Human Development2013;89(1):21-5. [DOI: 10.1016/j.earlhumdev.2012.07.003] [PMID: 22841551]">Bertini 2013</a>). </p> </section> <section id="CD013841-sec-0011"> <h3 class="title" id="CD013841-sec-0011">Description of the intervention</h3> <p>The use of skin antiseptics, such as chlorhexidine, in preparation for central catheter insertion has been one of the most critical steps in preventing CRBSI (<a href="./references#CD013841-bbs2-0043" title="MobleyRE , BizzarroMJ . Central line-associated bloodstream infections in the NICU: successes and controversies in the quest for zero. Seminars in Perinatology2017;41(3):166-74. [DOI: 10.1053/j.semperi.2017.03.006] [PMID: 28411947]">Mobley 2017</a>; <a href="./references#CD013841-bbs2-0060" title="UmscheidCA , MitchellMD , DoshiJA , AgarwalR , WilliamsK , BrennanPJ . Estimating the proportion of healthcare-associated infections that are reasonably preventable and the related mortality and costs. Infection Control and Hospital Epidemiology2011;32(2):101-14. [DOI: 10.1086/657912] [PMID: 21460463]">Umscheid 2011</a>). Studies show that skin antisepsis was effective in reducing the rate of skin colonisation in neonates, thus reducing the risk of CRBSI (<a href="./references#CD013841-bbs2-0018" title="ClimoMW , YokoeDS , WarrenDK , PerlTM , BolonM , HerwaldtLA , et al. Effect of daily chlorhexidine bathing on hospital-acquired infection. New England Journal of Medicine2013;368(6):533-42. [DOI: 10.1056/NEJMoa1113849] [PMID: 23388005]">Climo 2013</a>; <a href="./references#CD013841-bbs2-0030" title="JohnsonJ , SuwantaratN , ColantuoniE , RossTL , AucottSW , CarrollKC , et al. The impact of chlorhexidine gluconate bathing on skin bacterial burden of neonates admitted to the neonatal intensive care unit. Journal of Perinatology2019;39(1):63-71. [DOI: 10.1038/s41372-018-0231-7] [PMID: 30237474]">Johnson 2019</a>; <a href="./references#CD013841-bbs2-0058" title="SpencerC , OrrD , HallamS , TillmannsE . Daily bathing with octenidine on an intensive care unit is associated with a lower carriage rate of meticillin-resistant Staphylococcus aureus. Journal of Hospital Infection2013;83(2):156-9. [DOI: 10.1016/j.jhin.2012.10.007] [PMID: 23201399]">Spencer 2013</a>). For example, in an observational study, the use of chlorhexidine bathing reduced the bacterial burden on the arm and groin skin of neonates admitted to the NICU (<a href="./references#CD013841-bbs2-0030" title="JohnsonJ , SuwantaratN , ColantuoniE , RossTL , AucottSW , CarrollKC , et al. The impact of chlorhexidine gluconate bathing on skin bacterial burden of neonates admitted to the neonatal intensive care unit. Journal of Perinatology2019;39(1):63-71. [DOI: 10.1038/s41372-018-0231-7] [PMID: 30237474]">Johnson 2019</a>). In a previous neonatal RCT, Shah and colleagues found that 2% aqueous chlorhexidine solution (AQC) was equally effective compared to 2% chlorhexidine in 70% isopropyl alcohol (CHG‐IPA) before venipuncture in neonates (<a href="./references#CD013841-bbs2-0055" title="ShahV , DeshpandeP , LeeK , McGeerA , JainA . Comparison of 2% chlorhexidine in 70% isopropyl alcohol with 2% aqueous chlorhexidine for skin antisepsis prior to venepuncture in very low birth weight infants: a non-inferiority trial. Paediatrics &amp; Child Health2014;19:e67-8. [DOI: 10.1093/pch/19.6.e35-88]">Shah 2014</a>). Both solutions were able to clear bacterial colonisation on the venepuncture site equally without causing any cutaneous adverse reaction (<a href="./references#CD013841-bbs2-0055" title="ShahV , DeshpandeP , LeeK , McGeerA , JainA . Comparison of 2% chlorhexidine in 70% isopropyl alcohol with 2% aqueous chlorhexidine for skin antisepsis prior to venepuncture in very low birth weight infants: a non-inferiority trial. Paediatrics &amp; Child Health2014;19:e67-8. [DOI: 10.1093/pch/19.6.e35-88]">Shah 2014</a>). However, the rapid onset of action and broad‐spectrum bactericidal activity of alcohol may increase the effectiveness of chlorhexidine (<a href="./references#CD013841-bbs2-0052" title="SathiyamurthyS , BanerjeeJ , GodambeSV . Antiseptic use in the neonatal intensive care unit - a dilemma in clinical practice: an evidence based review. World Journal of Clinical Pediatrics2016;5(2):159-71. [DOI: 10.5409/wjcp.v5.i2.159] [PMID: 27170926]">Sathiyamurthy 2016</a>). Alcohol works best in concentrations of between 60% and 80% (<a href="./references#CD013841-bbs2-0052" title="SathiyamurthyS , BanerjeeJ , GodambeSV . Antiseptic use in the neonatal intensive care unit - a dilemma in clinical practice: an evidence based review. World Journal of Clinical Pediatrics2016;5(2):159-71. [DOI: 10.5409/wjcp.v5.i2.159] [PMID: 27170926]">Sathiyamurthy 2016</a>). </p> <p>There are different NICU practices on the antiseptic choices for central line insertion (<a href="./references#CD013841-bbs2-0042" title="McCordH , FieldhouseE , El-NaggarW . Current practices of antiseptic use in Canadian neonatal intensive care units. American Journal of Perinatology2019;36(2):141-7. [DOI: 10.1055/s-0038-1661406] [PMID: 29945280]">McCord 2019</a>). Most guidelines propose the use of chlorhexidine either in alcohol or aqueous solutions (<a href="./references#CD013841-bbs2-0039" title="LovedayHP , WilsonJA , PrattRJ , GolsorkhiM , TingleA , BakA , et al. epic3: National evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England. Journal of Hospital Infection2014;86(Suppl 1):S1-70. [DOI: 10.1016/S0195-6701(13)60012-2] [PMID: 24330862]">Loveday 2014</a>; <a href="./references#CD013841-bbs2-0045" title="O'GradyNP , AlexanderM , BurnsLA , DellingerEP , GarlandJ , HeardSO , et al. Guidelines for the prevention of intravascular catheter-related infections. Clinical Infectious Diseases2011;52(9):e162-93. [DOI: 10.1093/cid/cir257] [PMID: 21460264]">O'Grady 2011</a>). Other types of antiseptic solutions used in NICUs worldwide include various preparations of chlorhexidine, alcohol, povidone‐iodine (PI), and octenidine (<a href="./references#CD013841-bbs2-0052" title="SathiyamurthyS , BanerjeeJ , GodambeSV . Antiseptic use in the neonatal intensive care unit - a dilemma in clinical practice: an evidence based review. World Journal of Clinical Pediatrics2016;5(2):159-71. [DOI: 10.5409/wjcp.v5.i2.159] [PMID: 27170926]">Sathiyamurthy 2016</a>). In a survey in the USA in 2012, 61% of the NICUs used chlorhexidine as a skin antiseptic for central catheter insertion procedure (<a href="./references#CD013841-bbs2-0017" title="ChapmanAK , AucottSW , MilstoneAM . Safety of chlorhexidine gluconate used for skin antisepsis in the preterm infant. Journal of Perinatology2012;32(1):4-9. [DOI: 10.1038/jp.2011.148] [PMID: 22031047]">Chapman 2012</a>). An excellent antiseptic of choice should have: broad antibacterial coverage, including both gram negative and gram positive; with fast onset and long duration of action, the persistence of action despite contamination by organic materials such as blood; and a good safety profile (<a href="./references#CD013841-bbs2-0052" title="SathiyamurthyS , BanerjeeJ , GodambeSV . Antiseptic use in the neonatal intensive care unit - a dilemma in clinical practice: an evidence based review. World Journal of Clinical Pediatrics2016;5(2):159-71. [DOI: 10.5409/wjcp.v5.i2.159] [PMID: 27170926]">Sathiyamurthy 2016</a>). </p> </section> <section id="CD013841-sec-0012"> <h3 class="title" id="CD013841-sec-0012">How the intervention might work</h3> <p>Skin antiseptic can prevent infection of the catheter upon its placement and prevent bacterial colonisation and maintain the catheter site's sterility for up to 24 hours after application (<a href="./references#CD013841-bbs2-0052" title="SathiyamurthyS , BanerjeeJ , GodambeSV . Antiseptic use in the neonatal intensive care unit - a dilemma in clinical practice: an evidence based review. World Journal of Clinical Pediatrics2016;5(2):159-71. [DOI: 10.5409/wjcp.v5.i2.159] [PMID: 27170926]">Sathiyamurthy 2016</a>). These factors reduce the risk of extraluminal and intraluminal colonisation of the catheter by skin flora, which accounts for more than 80% of all causes of CRBSI (<a href="./references#CD013841-bbs2-0045" title="O'GradyNP , AlexanderM , BurnsLA , DellingerEP , GarlandJ , HeardSO , et al. Guidelines for the prevention of intravascular catheter-related infections. Clinical Infectious Diseases2011;52(9):e162-93. [DOI: 10.1093/cid/cir257] [PMID: 21460264]">O'Grady 2011</a>). Studies in paediatrics and adults have demonstrated a significant benefit with skin antiseptics for reducing the rate of CRBSI (<a href="./references#CD013841-bbs2-0039" title="LovedayHP , WilsonJA , PrattRJ , GolsorkhiM , TingleA , BakA , et al. epic3: National evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England. Journal of Hospital Infection2014;86(Suppl 1):S1-70. [DOI: 10.1016/S0195-6701(13)60012-2] [PMID: 24330862]">Loveday 2014</a>; <a href="./references#CD013841-bbs2-0045" title="O'GradyNP , AlexanderM , BurnsLA , DellingerEP , GarlandJ , HeardSO , et al. Guidelines for the prevention of intravascular catheter-related infections. Clinical Infectious Diseases2011;52(9):e162-93. [DOI: 10.1093/cid/cir257] [PMID: 21460264]">O'Grady 2011</a>). Due to the significant benefit, the use of antiseptic solution prior to invasive procedures has long been advocated by major neonatal guidelines globally. However, no consensus has been reached on the best antiseptic solution for the neonatal population (<a href="./references#CD013841-bbs2-0052" title="SathiyamurthyS , BanerjeeJ , GodambeSV . Antiseptic use in the neonatal intensive care unit - a dilemma in clinical practice: an evidence based review. World Journal of Clinical Pediatrics2016;5(2):159-71. [DOI: 10.5409/wjcp.v5.i2.159] [PMID: 27170926]">Sathiyamurthy 2016</a>). Concerns regarding the safety of antiseptic solutions in neonates have been raised because of the risk of intoxication and organ damage related to significant systemic absorption of antiseptics (<a href="./references#CD013841-bbs2-0052" title="SathiyamurthyS , BanerjeeJ , GodambeSV . Antiseptic use in the neonatal intensive care unit - a dilemma in clinical practice: an evidence based review. World Journal of Clinical Pediatrics2016;5(2):159-71. [DOI: 10.5409/wjcp.v5.i2.159] [PMID: 27170926]">Sathiyamurthy 2016</a>). These small infants have underdeveloped skin structures and renal excretion capability, both of which can lead to toxic accumulation of antiseptics (<a href="./references#CD013841-bbs2-0030" title="JohnsonJ , SuwantaratN , ColantuoniE , RossTL , AucottSW , CarrollKC , et al. The impact of chlorhexidine gluconate bathing on skin bacterial burden of neonates admitted to the neonatal intensive care unit. Journal of Perinatology2019;39(1):63-71. [DOI: 10.1038/s41372-018-0231-7] [PMID: 30237474]">Johnson 2019</a>; <a href="./references#CD013841-bbs2-0052" title="SathiyamurthyS , BanerjeeJ , GodambeSV . Antiseptic use in the neonatal intensive care unit - a dilemma in clinical practice: an evidence based review. World Journal of Clinical Pediatrics2016;5(2):159-71. [DOI: 10.5409/wjcp.v5.i2.159] [PMID: 27170926]">Sathiyamurthy 2016</a>). The use of topical PI as an antiseptic or dressing on infant skin is known to affect the thyroid function (<a href="./references#CD013841-bbs2-0040" title="MalhotraS , KumtaS , BhutadaA , Jacobson-DickmanE , MotaghediR . Topical iodine-induced thyrotoxicosis in a newborn with a giant omphalocele. American Journal of Perinatology Reports2016;6(2):e243-5. [DOI: 10.1055/s-0036-1584879] [PMID: 27551578]">Malhotra 2016</a>). Despite this, PI is still used in daily clinical practice and clinical trials (<a href="./references#CD013841-bbs2-0003" title="EUDRACT 2011-002962-19. Chlorhexidine versus povidone-iodine for skin anitsepsis prior to central venous catheter insertion in preterm infants: protocol for a randomised trial (the SKA trial). clinicaltrialsregister.eu/ctr-search/search?query=2011-002962-19 (first received 4 October 2011). KieranEA , O'SullivanA , MiletinJ , TwomeyAR , KnowlesSJ , O'DonnellCP . 2% chlorhexidine–70% isopropyl alcohol versus10% povidone–iodine for insertion site cleaningbefore central line insertion in preterm infants: a randomised trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2017;103(2):F101-6. [DOI: 10.1136/archdischild-2016-312193] [PMID: 29074717]">Kieran 2018</a>; <a href="./references#CD013841-bbs2-0042" title="McCordH , FieldhouseE , El-NaggarW . Current practices of antiseptic use in Canadian neonatal intensive care units. American Journal of Perinatology2019;36(2):141-7. [DOI: 10.1055/s-0038-1661406] [PMID: 29945280]">McCord 2019</a>). Chlorhexidine and alcohol itself are also not without problems. There have been reported cases of local side effects, such as chemical burns and contact dermatitis, and chlorhexidine is not licenced for infants less than two months old (<a href="./references#CD013841-bbs2-0042" title="McCordH , FieldhouseE , El-NaggarW . Current practices of antiseptic use in Canadian neonatal intensive care units. American Journal of Perinatology2019;36(2):141-7. [DOI: 10.1055/s-0038-1661406] [PMID: 29945280]">McCord 2019</a>; <a href="./references#CD013841-bbs2-0044" title="NeriI , RavaioliGM , FaldellaG , CaprettiMG , ArcuriS , PatriziA . Chlorhexidine-induced chemical burns in very low birth weight infants. Journal of Pediatrics2017;191:262-5.e2. [DOI: 10.1016/j.jpeds.2017.08.002] [PMID: 29173315]">Neri 2017</a>; <a href="./references#CD013841-bbs2-0049" title="PaternosterM , NiolaM , GrazianoV . Avoiding chlorhexidine burns in preterm infants. Journal of Obstetric, Gynecologic, and Neonatal Nursing2017;46(2):267-71. [DOI: 10.1016/j.jogn.2016.10.007] [PMID: 28068508]">Paternoster 2017</a>). There is also concern about the neurotoxic effect of chlorhexidine in preterm neonates (<a href="./references#CD013841-bbs2-0052" title="SathiyamurthyS , BanerjeeJ , GodambeSV . Antiseptic use in the neonatal intensive care unit - a dilemma in clinical practice: an evidence based review. World Journal of Clinical Pediatrics2016;5(2):159-71. [DOI: 10.5409/wjcp.v5.i2.159] [PMID: 27170926]">Sathiyamurthy 2016</a>), and the risk of allergy and anaphylaxis (<a href="./references#CD013841-bbs2-0046" title="OdedraKM , FarooqueS . Chlorhexidine: an unrecognised cause of anaphylaxis. Postgraduate Medical Journal2014;90(1070):709-14. [DOI: 10.1136/postgradmedj-2013-132291] [PMID: 25352674]">Odedra 2014</a>). </p> </section> <section id="CD013841-sec-0013"> <h3 class="title" id="CD013841-sec-0013">Why it is important to do this review</h3> <p>Chlorhexidine has become the standard in adult guidelines supported by various studies that have shown significant benefit of chlorhexidine compared to PI (<a href="./references#CD013841-bbs2-0020" title="DarouicheRO , Wall MJ Jr, ItaniKM , OttersonMF , WebbAL , CarrickMM , et al. Chlorhexidine-alcohol versus povidone-iodine for surgical-site antisepsis. New England Journal of Medicine2010;362(1):18-26. [DOI: 10.1056/NEJMoa0810988] [PMID: 20054046]">Darouiche 2010</a>; <a href="./references#CD013841-bbs2-0045" title="O'GradyNP , AlexanderM , BurnsLA , DellingerEP , GarlandJ , HeardSO , et al. Guidelines for the prevention of intravascular catheter-related infections. Clinical Infectious Diseases2011;52(9):e162-93. [DOI: 10.1093/cid/cir257] [PMID: 21460264]">O'Grady 2011</a>). However, neonatal guidelines are still uncertain due to a lack of studies comparing the two most commonly used antiseptic solutions, chlorhexidine and PI (<a href="./references#CD013841-bbs2-0050" title="PonnusamyV , VenkateshV , ClarkeP . Skin antisepsis in the neonate: what should we use?Current Opinion in Infectious Diseases2014;27(3):244-50. [DOI: 10.1097/QCO.0000000000000064] [PMID: 24751895]">Ponnusamy 2014</a>; <a href="./references#CD013841-bbs2-0052" title="SathiyamurthyS , BanerjeeJ , GodambeSV . Antiseptic use in the neonatal intensive care unit - a dilemma in clinical practice: an evidence based review. World Journal of Clinical Pediatrics2016;5(2):159-71. [DOI: 10.5409/wjcp.v5.i2.159] [PMID: 27170926]">Sathiyamurthy 2016</a>). Most NICUs use either a preparation of chlorhexidine in aqueous or in an alcohol solution. Few NICUs still use PI solution (<a href="./references#CD013841-bbs2-0052" title="SathiyamurthyS , BanerjeeJ , GodambeSV . Antiseptic use in the neonatal intensive care unit - a dilemma in clinical practice: an evidence based review. World Journal of Clinical Pediatrics2016;5(2):159-71. [DOI: 10.5409/wjcp.v5.i2.159] [PMID: 27170926]">Sathiyamurthy 2016</a>). There is uncertainty regarding which concentration of chlorhexidine, whether in aqueous or alcohol, is the most appropriate, and worries exist around developing resistance to chlorhexidine (<a href="./references#CD013841-bbs2-0031" title="KampfG . Acquired resistance to chlorhexidine - is it time to establish an 'antiseptic stewardship' initiative?Journal of Hospital Infection2016;94(3):213-27. [DOI: 10.1016/j.jhin.2016.08.018] [PMID: 27671220]">Kampf 2016</a>)<b>.</b> Uncertainties on the effectiveness of the antiseptic solution in the neonatal population, the relative effectiveness of one antiseptic solution over another, concerns regarding the development of resistance and their safety profile in this vulnerable population, and the variation in practice warrant an up‐to‐date and rigorous synthesis of evidence in a systematic review. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013841-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013841-sec-0014"></div> <p>To systematically evaluate the safety and efficacy of different antiseptic solutions in preventing CRBSI and other related outcomes in neonates with CVC. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013841-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013841-sec-0015"></div> <section id="CD013841-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013841-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included RCTs or cluster‐RCTs at the NICU level comparing any antiseptic solution (single or in combination) against any other type of antiseptic solution, or no antiseptic solution, or placebo in preparation for central catheter insertion. We excluded cross‐over trials because we considered that the infants' risks of developing sepsis and other catheter‐related complications are not constant across time. We excluded quasi‐RCTs. </p> </section> <section id="CD013841-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included trials that recruited neonates born at any gestational age, preterm or full term, nursed in a NICU with a planned CVC insertion. The number of infants was the unit of analysis and all the infants had only one catheter at any time. We included studies that used umbilical venous catheters (UVCs) and peripherally inserted central catheters (PICC). We only included trials that used the same catheter or dressing material in both groups, and neonates from both groups received similar care and co‐interventions. </p> </section> <section id="CD013841-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Chlorhexidine as a single agent or a combination of antiseptic solutions containing chlorhexidine against another antiseptic solution, placebo, or no solution prior to CVC insertion. The solution needed to be applied immediately prior to the insertion of the catheter and not reapplied during dressing changes. However, we accepted trials that reapply the antiseptic solution during dressing changes provided that it was done in both trial arms and no placebo was used. The selection, insertion, use, maintenance, and removal of the CVC and the dressing had to follow the standard protocol as specified in the individual study in both the intervention and comparison groups. There could be no difference in the catheter material, including the presence or absence of antimicrobial impregnation or other catheter‐related antimicrobial technologies and concurrent infection control measures, between the intervention and comparison group. </p> <section id="CD013841-sec-0020"> <h5 class="title">Experimental</h5> <p>In trials that used chlorhexidine in one of the trial arms, we considered 2% chlorhexidine in concentrations of alcohol between 60% and 80% to be the experimental group. The intervention had to be applied only once before catheter insertion. Each recruited infant could have had only one CVC inserted at one time. For trials comparing different concentrations of chlorhexidine other than 2%, the highest concentration was selected as the experimental group. </p> </section> <section id="CD013841-sec-0021"> <h5 class="title">Comparator</h5> <p>We chose chlorhexidine in aqueous, placebo, no antiseptic solution, or antiseptic solution other than chlorhexidine either alone or in combination as comparator. We considered the lower concentration of chlorhexidine as the comparator if the trial compared the same antiseptic solutions.  </p> </section> </section> <section id="CD013841-sec-0022"> <h4 class="title">Types of outcome measures</h4> <section id="CD013841-sec-0023"> <h5 class="title">Primary outcomes</h5> <p>We have based our outcomes on a related Cochrane Review (<a href="./references#CD013841-bbs2-0035" title="LaiNM , TaylorJE , TanK , ChooYM , Ahmad KamarA , MuhamadNA . Antimicrobial dressings for the prevention of catheter-related infections in newborn infants with central venous catheters. Cochrane Database of Systematic Reviews2016, Issue 3. Art. No: CD011082. [DOI: 10.1002/14651858.CD011082.pub2] [PMID: 27007217]">Lai 2016</a>). Our outcomes were as follows. </p> <p> <ol id="CD013841-list-0001"> <li> <p><b>Proven CRBSI using absolute rates of infants</b>. We employed the definition of CRBSI based on the CDC and the Infectious Disease Society of America (IDSA) criteria (<a href="./references#CD013841-bbs2-0015" title="O’GradyNP , AlexanderM , BurnsLA , DellingerP , GarlandJ , HeardS , et al, the Healthcare Infection Control Practices Advisory Committee (HICPAC). Guidelines for the prevention of intravascular catheter-related infections, 2011. www.cdc.gov/infectioncontrol/pdf/guidelines/bsi-guidelines-H.pdf (accessed prior to 15 December 2020).">CDC 2011</a>; <a href="./references#CD013841-bbs2-0041" title="ManianFA . IDSA guidelines for the diagnosis and management of intravascular catheter-related bloodstream infection. Clinical Infectious Diseases2009;49(11):1770-1; author reply 1771-2. [DOI: 10.1086/648113] [PMID: 19891568]">Manian 2009</a>). This included the growth of an identical organism from cultures of central catheter parts upon removal or from blood withdrawn from it (in large catheters), and blood withdrawn from peripheral veins with the presence of clinical signs and symptoms of sepsis in the absence of another infection from a distant site. Additionally, the ratio of the colony count of microorganisms grown from the central catheter parts to the colony count of blood from the peripheral vein had to be at least 3:1, and the growth from the central catheter parts or blood withdrawn from it had to occur at least two hours before any detected growth in the peripheral blood sample. In the case of neonatal deaths, there is a positive culture from sterile sites (e.g. cardiac, cerebrospinal fluid, liver, and spleen) at autopsy. We chose CRBSI as it has higher specificity in confirming that the catheter is the source of infection compared to CLABSI. We accepted trials that used overlapping definitions of CRBSI and CLABSI under this outcome if CRBSI was not independently reported. Catheter segment culture is costly, has a high false‐positivity (<a href="./references#CD013841-bbs2-0033" title="KitanoT , TakagiK , AraiI , YasuharaH , EbisuR , OhgitaniA , et al. Efficacy of routine catheter tip culture in a neonatal intensive care unit. Pediatrics International2018;60(5):423-7. [DOI: 10.1111/ped.13538] [PMID: 29468780]">Kitano 2018</a>), and is no longer a routine investigation in most NICUs. Furthermore, not all infants with probable CRBSI have their CVC removed and cultured, and it is not feasible to withdraw blood for culture from the small neonatal PICC (<a href="./references#CD013841-bbs2-0012" title="BentlinMR , RugoloLM , FerrariLS . Practices related to late-onset sepsis in very low-birth weight preterm infants. Jornal de Pediatria2015;91(2):168-74. [DOI: 10.1016/j.jped.2014.07.004] [PMID: 25449788]">Bentlin 2015</a>).  </p> </li> <li> <p><b>CLABSI using absolute rates of infants.</b> We used the definition of CLABSI in patient ≤ one‐year‐old, adapted from the previous version of <a href="./references#CD013841-bbs2-0016" title="Centers for Disease Control and Prevention (CDC). Bloodstream infection event (central line-associated bloodstream infection and non-central line associated bloodstream infection). January 2023. www.cdc.gov/nhsn/pdfs/pscmanual/4psc_clabscurrent.pdf (accessed 19 January 2023).">CDC 2023</a>. The definition included all the following criteria: </p> <ol id="CD013841-list-0002"> <li> <p>presence of at least one of the following:</p> <ol id="CD013841-list-0003"> <li> <p>fever (more than 38 ºC core temperature);</p> </li> <li> <p>hypothermia (less than 36 ºC core temperature);</p> </li> <li> <p>apnoea or bradycardia;</p> </li> </ol> </li> <li> <p>positive peripheral blood culture not related to an infection at another site;</p> </li> <li> <p>the same common commensal organism listed in the CDC common commensal organism list is cultured from two or more blood cultures drawn on separate occasions within 24 hours duration. </p> </li> <li> <p>presence of a central line on the day of the event or in the last 24 hours. </p> </li> </ol> </li> <li> <p><b>Probable or clinical sepsis of all causes measured by the authors of individual trials as absolute rates of infants up to 24 hours after removal of the catheter</b>. We used a broad definition of probable or clinical sepsis adapted from <a href="./references#CD013841-bbs2-0062" title="WynnJL , WongHR , ShanleyTP , BizzarroMJ , SaimanL , PolinRA . Time for a neonatal-specific consensus definition for sepsis. Pediatric Critical Care Medicine2014;15(6):523-8. [DOI: 10.1097/PCC.0000000000000157] [PMID: 24751791]">Wynn 2014</a>. The criteria excluded the cases of proven sepsis and included all the following criteria: </p> <ol id="CD013841-list-0004"> <li> <p>the presence of at least one of the following:</p> <ol id="CD013841-list-0005"> <li> <p>fever (more than 38 ºC core temperature);</p> </li> <li> <p>hypothermia (less than 36 ºC core temperature);</p> </li> <li> <p>apnoea or bradycardia;</p> </li> </ol> </li> <li> <p>no positive blood culture;</p> </li> <li> <p>a combination of at least two clinical or laboratory signs of sepsis;</p> </li> <li> <p>no apparent source of infection from another site;</p> </li> <li> <p>the clinical features have led to the institution of treatment for sepsis.</p> </li> </ol> </li> <li> <p><b>All‐cause mortality before discharge from the NICU.</b> </p> </li> <li> <p><b>Chemical burns or contact dermatitis,</b> measured using a scoring system or by clinical judgement as described by the trial authors during or after the application of the antiseptic solution. </p> </li> </ol> </p> </section> <section id="CD013841-sec-0024"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD013841-list-0006"> <li> <p><b>The proportion of infants with catheter colonisation</b> , defined as significant growth of a microorganism (more than 15 colony‐forming units) <b>from a segment of the catheter</b>, or positive catheter hub culture with negative percutaneous blood culture taken simultaneously, in the absence of clinical signs of infection (<a href="./references#CD013841-bbs2-0024" title="GahlotR , NigamC , KumarV , YadavG , AnupurbaS . Catheter-related bloodstream infections. International Journal of Critical Illness and Injury Science2014;4(2):162-7. [DOI: 10.4103/2229-5151.134184] [PMID: 25024944]">Gahlot 2014</a>; <a href="./references#CD013841-bbs2-0041" title="ManianFA . IDSA guidelines for the diagnosis and management of intravascular catheter-related bloodstream infection. Clinical Infectious Diseases2009;49(11):1770-1; author reply 1771-2. [DOI: 10.1086/648113] [PMID: 19891568]">Manian 2009</a>). </p> </li> <li> <p><b>Premature central line removal</b>, defined as the number of CVC removed in the trial as deemed by the trial author as the source of infection. </p> </li> <li> <p><b>The proportion of infants or catheters with exit‐site infection</b>, either microbiologically documented (i.e. exudates at the catheter exit site growing a microorganism with or without concomitant bloodstream infections) or clinically documented (i.e. erythema or induration within 2 cm of the catheter exit site in the absence of associated bloodstream infections and without concomitant purulence (<a href="./references#CD013841-bbs2-0048" title="PaganiJL , EggimannP . Management of catheter-related infection. Expert Review of Anti-Infective Therapy2008;6(1):31-7. [DOI: 10.1586/14787210.6.1.31] [PMID: 18251662]">Pagani 2008</a>), assessed throughout the in‐dwelling period of the catheter). </p> </li> <li> <p><b>The proportion of infants with antiseptic‐resistant organisms from cultures, including exit site cultures, catheter cultures, and blood cultures,</b> assessed throughout their NICU stay. </p> </li> <li> <p><b>Antibiotic usage during hospitalisation assessed throughout the in‐dwelling period of the catheter,</b> either the proportion of infants that required antibiotics due to suspected or proven infection (as detailed in primary outcome numbers one (proven CRBSI), two (CLABSI), and three (probable or clinical sepsis of all causes)) or the mean duration of antibiotics use.  </p> </li> <li> <p><b>Length of hospitalisation in days</b>. </p> </li> <li> <p><b>Thyroid dysfunction,</b> defined as deranged serum level of thyroid stimulating hormone, free thyroxine (T4), or T4 with or without clinical signs of hypothyroidism as defined by the trial authors. </p> </li> <li> <p><b>Allergy and anaphylaxis,</b> defined by the trial authors using valid diagnostic criteria. </p> </li> <li> <p><b>Neurodevelopmental outcome at approximately between 18 months and 28 months of age (corrected age of approximately 24 months) including;</b> cerebral palsy, significant mental developmental delay (Bayley Scales of Infant Development Mental Developmental Index &lt; 70) (<a href="./references#CD013841-bbs2-0011" title="BayleyB . Bayley Scales of Infant and Toddler Development. 3rd edition. Toronto: PsychCorp, Pearson, 2006.">Bayley 2006</a>), or Griffiths Mental Development Scale assessment (more than two standard deviations (SDs) below the mean) (<a href="./references#CD013841-bbs2-0026" title="GreenE , StroudL , BloomfieldS , CronjeJ , FoxcroftC , HurterK . Griffiths Scales of Child Development. 3rd edition. Oxford (UK): Hogrefe, 2016.">Griffiths 2016</a>), legal blindness (&lt; 20/200 visual acuity) (<a href="./references#CD013841-bbs2-0036" title="LeeSY , MesfinFB . Blindness. ncbi.nlm.nih.gov/books/NBK448182/ (accessed 1 July 2022). [PMID: 28846303]">Lee 2022</a>), and sensorineural deafness requiring amplification (<a href="./references#CD013841-bbs2-0029" title="JacobsSE , BergM , HuntR , Tarnow-MordiWO , InderTE , DavisPG . Cooling for newborns with hypoxic ischaemic encephalopathy. Cochrane Database of Systematic Reviews2013, Issue 1. Art. No: CD003311. [DOI: 10.1002/14651858.CD003311.pub3] [PMID: 23440789]">Jacobs 2013</a>). </p> </li> </ol> </p> </section> </section> </section> <section id="CD013841-sec-0025"> <h3 class="title">Search methods for identification of studies</h3> <p>The Neonatal Group Information Specialist developed search strategies in consultation with the review authors (<a href="./appendices#CD013841-sec-0102">Appendix 1</a>). The MEDLINE strategy was peer‐reviewed by an Information Specialist before translating for other databases.  </p> <section id="CD013841-sec-0026"> <h4 class="title">Electronic searches</h4> <p>The following databases were searched without language, publication year, publication type, or publication status restrictions: </p> <p> <ul id="CD013841-list-0007"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL), via Wiley (Issue 3, March 2022); </p> </li> <li> <p>Cochrane Database of Systematic Reviews, via Wiley (Issue 3, 2022);</p> </li> <li> <p>Ovid MEDLINE and Epub Ahead of Print, In‐Process, In‐Data‐Review &amp; Other Non‐Indexed Citations and Daily (1946 to 22 April 2022); </p> </li> <li> <p>Embase, OVID (1974 to 22 April 2022).</p> </li> </ul> </p> </section> <section id="CD013841-sec-0027"> <h4 class="title">Searching other resources</h4> <p>Trial registration records were identified using CENTRAL and by independent searches of: </p> <p> <ul id="CD013841-list-0008"> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a>); and </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="https://trialsearch.who.int/Default.aspx" target="_blank">trialsearch.who.int/Default.aspx</a>). </p> </li> </ul> </p> <p>Conference abstracts were identified using CENTRAL, Embase, and the following conference websites: </p> <p> <ul id="CD013841-list-0009"> <li> <p>Eastern Society for Pediatric Research (ESPR) (<a href="https://eastern-spr.org/#archives" target="_blank">www.easternspr.org/meeting/#archives</a>); </p> </li> <li> <p>Pediatric Academic Societies (PAS) (<a href="https://www.pas-meeting.org/past-abstracts/" target="_blank">www.pas-meeting.org/past-abstracts/</a>). </p> </li> </ul> </p> <p>We screened the reference lists of included or related trials (e.g. in the subject area of our review but not eligible for inclusion), or both, and related systematic reviews (e.g. reviews including the population or intervention examined in our review) for trials not identified by the database searches.  </p> </section> </section> <section id="CD013841-sec-0028"> <h3 class="title" id="CD013841-sec-0028">Data collection and analysis</h3> <p>We collected information regarding the method of randomisation, blinding, intervention, stratification, and whether the trial was single or multicentre for each included trial. We noted information regarding trial participants, including: description of the study population; location and social context of the trial population; inclusion and exclusion criteria; the total number of participants randomised; baseline characteristic imbalances; socio‐demographics information including gestational age; the age of participants at recruitment; birth and body weight at recruitment; gender and race; and any reported or measured subgroups, as well as the number of participants randomised and analysed for each arm. </p> <section id="CD013841-sec-0029"> <h4 class="title">Selection of studies</h4> <p>We included all RCTs or cluster‐RCTs at the NICU level that fulfilled our inclusion criteria. Two review authors (MMH, IA) independently assessed the search results and selected the trials for inclusion using the predefined inclusion and exclusion criteria. We resolved disagreements by discussion and through a third review author (HVR) who acted as arbiter. We recorded detailed descriptions of all included trials in a '<a href="./references#CD013841-sec-0119" title="">Characteristics of included studies</a>' table. </p> <p>We recorded the selection process in sufficient detail to complete a PRISMA flow diagram (<a href="#CD013841-fig-0001">Figure 1</a>), and '<a href="./references#CD013841-sec-0120" title="">Characteristics of excluded studies</a>' table. We accepted all published and unpublished trials, both in full article and abstract form, with sufficient information to complete the 'Risk of bias' assessments. </p> <div class="figure" id="CD013841-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD013841-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_n/nCD013841-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD013841-sec-0030"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (EM, IA) independently extracted, assessed, and coded all data from each included trial using a pro forma designed exclusively for this review that was integrated with a modified version of the Cochrane Effective Practice and Organisation of Care (EPOC) Group data collection checklist (<a href="./references#CD013841-bbs2-0019" title="Cochrane Effective Practice and Organisation of Care (EPOC). Screening, data extraction and management. EPOC resources for review authors, 2017. epoc.cochrane.org/epoc-resources-review-authors (accessed 20 June 2020).">Cochrane EPOC Group 2017</a>). </p> <p>We extracted the following characteristics from each included trial:</p> <p> <ul id="CD013841-list-0010"> <li> <p>general information: trial author(s); published or unpublished; year of publication; the year in which trial was conducted; possible conflicts of interest; details of other relevant papers cited; </p> </li> <li> <p>trial design and setting: trial design; type, duration, blinding of participants and outcomes and completeness of follow‐up (e.g. greater than 80%); country and location of trial; informed consent; ethics approval; </p> </li> <li> <p>participants: sex, birth weight, gestational age, age and weight at recruitment, eligibility criteria, number of participants, cluster (if applicable), unit of allocation (e.g. individuals or catheters); </p> </li> <li> <p>interventions: type of antiseptic solution, concentration, comparator, number randomised to the group, co‐interventions (e.g. dressing, type of catheters, lock therapy); </p> </li> <li> <p>outcomes, as described in <a href="#CD013841-sec-0022">Types of outcome measures</a>. </p> </li> </ul> </p> <p>We resolved all disagreements by discussion. Two review authors (MMH, EM) entered the final data of the included trials into <a href="./references#CD013841-bbs2-0051" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a> and cross‐checked each other's entries. All review authors reviewed the analyses, and draft manuscript. </p> <p>We contacted the authors of unpublished trials to request further information, including details on the methods of sequence generation, allocation and blinding, participant withdrawal, prespecified outcomes, and full outcome data, to permit inclusion in meta‐analysis. We did not find any trials available only as abstracts. We included final data from each trial and not data from interim analyses. </p> </section> <section id="CD013841-sec-0031"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (IA, MMH) independently assessed the risk of bias (low, high, or unclear) of all included trials using the Cochrane ‘Risk of bias’ tool (<a href="./references#CD013841-bbs2-0027" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Higgins 2020</a>), for the following domains: </p> <p> <ul id="CD013841-list-0011"> <li> <p>sequence generation (selection bias);</p> </li> <li> <p>allocation concealment (selection bias);</p> </li> <li> <p>blinding of participants and personnel (performance bias);</p> </li> <li> <p>blinding of outcome assessment (detection bias);</p> </li> <li> <p>incomplete outcome data (attrition bias);</p> </li> <li> <p>selective reporting (reporting bias);</p> </li> <li> <p>any other bias.</p> </li> </ul> </p> <p>We resolved all disagreements through discussion and by consulting a third review author (NML). See <a href="./appendices#CD013841-sec-0103">Appendix 2</a> for a more detailed description of the risk of bias for each domain. </p> </section> <section id="CD013841-sec-0032"> <h4 class="title">Measures of treatment effect</h4> <p>We performed the statistical analyses using <a href="./references#CD013841-bbs2-0051" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a> software. We analysed dichotomous data using risk ratio (RR) and risk difference (RD) with 95% confidence intervals (CIs). We calculated the number needed to treat for an additional beneficial outcome (NNTB) or the number needed to treat for an additional harmful outcome (NNTH) in a statistically significant outcome.  </p> </section> <section id="CD013841-sec-0033"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the number of participating infants in individual randomised trials, and each infant was considered only once in the analysis. We anticipated two significant categories of unit of analysis errors: first, those related to trials that report outcomes using catheters rather than infants as the unit of analysis; and second, those related to cluster‐RCTs where infants were incorrectly analysed as the unit of allocation. </p> </section> <section id="CD013841-sec-0034"> <h4 class="title">Dealing with missing data</h4> <p>We analysed missing data as follows:</p> <p> <ul id="CD013841-list-0012"> <li> <p>if the missing data were deemed not significant enough to cause concern i.e. less than 20% or the number of missing data were less than the difference between the events in intervention and control groups, and we could not find the reason for missing data from the trial or after contacting the trial authors, we assumed that the data were missing at random. We analysed only the available data (i.e. ignoring the missing data) and then performed a modified intention‐to‐treat analysis; </p> </li> <li> <p>if the missing data were deemed large enough to cause concern, we imputed with the assumption that all would have a poor outcome. </p> </li> </ul> </p> </section> <section id="CD013841-sec-0035"> <h4 class="title">Assessment of heterogeneity</h4> <p>We estimated the treatment effects of individual trials and examined heterogeneity amongst trials by inspecting the forest plots and by quantifying the impact of heterogeneity using the I² statistic. We graded the degree of heterogeneity as follows:  </p> <p> <ul id="CD013841-list-0013"> <li> <p>I² &lt; 25%, no heterogeneity; </p> </li> <li> <p>I² 25% to 49%, low heterogeneity; </p> </li> <li> <p>I² 50% to 75%, moderate heterogeneity; </p> </li> <li> <p>I² &gt; 75%, substantial heterogeneity.</p> </li> </ul> </p> </section> <section id="CD013841-sec-0036"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed reporting bias by comparing the stated primary outcomes and secondary outcomes and the reported outcomes. We compared the full publications with trial protocols when available, to determine the likelihood of reporting bias. We documented trials using the interventions in a potentially eligible infant population but not reporting any of the primary and secondary outcomes of our review in the '<a href="./references#CD013841-sec-0119" title="">Characteristics of included studies</a>' table. </p> </section> <section id="CD013841-sec-0037"> <h4 class="title">Data synthesis</h4> <p>We performed meta‐analyses using <a href="./references#CD013841-bbs2-0051" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>. For categorical outcomes, we calculated the typical estimates of RR and RD, each with its 95% CI. There was no continuous outcome for analysis, and if available, we would have calculated the MD or the SMD, each with its 95% CI as detailed under <a href="#CD013841-sec-0032">Measures of treatment effect</a>. We used a fixed‐effect model to estimate the mean of a distribution of effects following the recommendations of the Cochrane Neonatal Review Group. We analysed and interpreted individual trials separately where meta‐analysis was deemed inappropriate. </p> </section> <section id="CD013841-sec-0038"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned for subgroup analysis for the following groups where data would have been available: </p> <p> <ul id="CD013841-list-0014"> <li> <p>different types of CVC: UVC, percutaneous long line, and other types of CVC;</p> </li> <li> <p>gestational age: preterm versus term;</p> </li> <li> <p>CVC with antimicrobial modifications (antimicrobial impregnation, cuffs, hubs) versus CVC with no antimicrobial modifications; </p> </li> <li> <p>trials involving clearly documented co‐interventions (e.g. a sepsis‐prevention bundle) applied in both groups versus trials involving no clearly documented co‐interventions. </p> </li> </ul> </p> <p>However, we were unable to perform any subgroup analysis due to an insufficient number of trials. </p> </section> <section id="CD013841-sec-0039"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform sensitivity analyses in the following situations:</p> <p> <ul id="CD013841-list-0015"> <li> <p>if there was unexplained moderate to high heterogeneity, we would have explored this by removing the outlying trial/trials causing heterogeneity (if feasible); </p> </li> <li> <p>if we had included a trial with a high risk of selection bias or attrition bias in the meta‐analysis of an outcome, where the other trials have a low risk of bias, we would have assessed the impact of removing the trial with a high risk of bias on the pooled estimate. </p> </li> </ul> </p> </section> <section id="CD013841-sec-0040"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used the GRADE approach, as outlined in the GRADE Handbook (<a href="./references#CD013841-bbs2-0054" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.">Schünemann 2013</a>), to assess the certainty of the evidence of the following outcomes: </p> <p> <ul id="CD013841-list-0016"> <li> <p>proven CRBSI expressed by the authors of the individual trials as absolute rates of infants; </p> </li> <li> <p>CLABSI as absolute rates of infants;</p> </li> <li> <p>chemical burns or contact dermatitis, measured using a scoring system or by clinical judgement as described by the trial author during or after the application of antiseptic solutions; </p> </li> <li> <p>all‐cause mortality throughout the hospital admission of the participant;</p> </li> <li> <p>the proportion of infants or catheters with exit‐site infection, either microbiologically or clinically documented; </p> </li> <li> <p>premature central line removal, defined as the number of CVCs removed in the trial as deemed by the author as the source of infection. </p> </li> </ul> </p> <p>Two review authors (HVR, MMH) independently assessed the certainty of the evidence for each of the outcomes listed above. We considered evidence from RCTs as high certainty but downgraded the evidence by one level for serious (or two levels for very serious) limitations based upon the following: design (risk of bias), consistency across trials, directness of the evidence, precision of estimates, and presence of publication bias. We used <a href="./references#CD013841-bbs2-0025" title="GRADEpro GDT. Version accessed 5 June 2020. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT</a> to create <a href="./full#CD013841-tbl-0001">summary of findings Table 1</a> and <a href="./full#CD013841-tbl-0002">summary of findings Table 2</a> to report the certainty of the evidence. The GRADE approach results in an assessment of the certainty of a body of evidence as one of four grades. </p> <p> <ul id="CD013841-list-0017"> <li> <p>High: we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>Moderate: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> </li> <li> <p>Low: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013841-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013841-sec-0041"></div> <section id="CD013841-sec-0042"> <h3 class="title">Description of studies</h3> <p>The flow diagram of the trials from the initial search to the meta‐analysis is shown in <a href="#CD013841-fig-0001">Figure 1</a>. </p> <section id="CD013841-sec-0043"> <h4 class="title">Results of the search</h4> <p>Database, trial registries, and non‐database searches identified 1836 references. After removing 496 duplicates, we screened 1340 records. We excluded 1333 records during title/abstract screening; assessed seven full‐texts; excluded four with reasons; and included three trials in our analysis. We identified no ongoing trials and placed no trials in the awaiting classification section. The full search strategies are presented in <a href="./appendices#CD013841-sec-0102">Appendix 1</a>.  </p> </section> <section id="CD013841-sec-0044"> <h4 class="title">Included studies</h4> <p>We included three RCTs (<a href="./references#CD013841-sec-0119" title="">Characteristics of included studies</a>). All included trials used individual infants as the unit of analysis. There was no duplicated entry of participants after matching the initial number of participants recruited against the total numbers at each step in the trial. <a href="./references#CD013841-bbs2-0003" title="EUDRACT 2011-002962-19. Chlorhexidine versus povidone-iodine for skin anitsepsis prior to central venous catheter insertion in preterm infants: protocol for a randomised trial (the SKA trial). clinicaltrialsregister.eu/ctr-search/search?query=2011-002962-19 (first received 4 October 2011). KieranEA , O'SullivanA , MiletinJ , TwomeyAR , KnowlesSJ , O'DonnellCP . 2% chlorhexidine–70% isopropyl alcohol versus10% povidone–iodine for insertion site cleaningbefore central line insertion in preterm infants: a randomised trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2017;103(2):F101-6. [DOI: 10.1136/archdischild-2016-312193] [PMID: 29074717]">Kieran 2018</a> was conducted in Ireland, <a href="./references#CD013841-bbs2-0001" title="ClarkeP , CraigJV , WainJ , TremlettC , LinsellL , BowlerU , et al. Safety and efficacy of 2% chlorhexidine gluconate aqueous versus 2% chlorhexidine gluconate in 70% isopropyl alcohol for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: the ARCTIC randomised-controlled feasibility trial protocol. BMJ Open2019;9(2):e028022. [DOI: 10.1136/bmjopen-2018-028022] [PMID: 30782955]ISRCTN82571474. Skin antiseptic trial for insertion of central venous catheters in neonates [The efficacy and safety of two topical antiseptic solutions for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: a feasibility study]. isrctn.com/ISRCTN82571474 (first received 7 July 2016). ">Clarke 2019</a> in the UK, and <a href="./references#CD013841-bbs2-0002" title="GarlandJS , AlexCP , UhingMR , PetersideIE , RentzA , HarrisMC . Pilot trial to compare tolerance of chlorhexidine gluconate to povidone-iodine antisepsis for central venous catheterplacement in neonates. Journal of Perinatology2009;29(12):808-13. [DOI: 10.1038/jp.2009.161] [PMID: 19812587]GarlandJS . Trial protocol enquiries. Email to: JS Garland 31 March 2021. ">Garland 2009</a> in the USA. All trials were multicentre and done in tertiary NICUs. The number of neonates enroled in <a href="./references#CD013841-bbs2-0003" title="EUDRACT 2011-002962-19. Chlorhexidine versus povidone-iodine for skin anitsepsis prior to central venous catheter insertion in preterm infants: protocol for a randomised trial (the SKA trial). clinicaltrialsregister.eu/ctr-search/search?query=2011-002962-19 (first received 4 October 2011). KieranEA , O'SullivanA , MiletinJ , TwomeyAR , KnowlesSJ , O'DonnellCP . 2% chlorhexidine–70% isopropyl alcohol versus10% povidone–iodine for insertion site cleaningbefore central line insertion in preterm infants: a randomised trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2017;103(2):F101-6. [DOI: 10.1136/archdischild-2016-312193] [PMID: 29074717]">Kieran 2018</a>, <a href="./references#CD013841-bbs2-0001" title="ClarkeP , CraigJV , WainJ , TremlettC , LinsellL , BowlerU , et al. Safety and efficacy of 2% chlorhexidine gluconate aqueous versus 2% chlorhexidine gluconate in 70% isopropyl alcohol for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: the ARCTIC randomised-controlled feasibility trial protocol. BMJ Open2019;9(2):e028022. [DOI: 10.1136/bmjopen-2018-028022] [PMID: 30782955]ISRCTN82571474. Skin antiseptic trial for insertion of central venous catheters in neonates [The efficacy and safety of two topical antiseptic solutions for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: a feasibility study]. isrctn.com/ISRCTN82571474 (first received 7 July 2016). ">Clarke 2019</a>, and <a href="./references#CD013841-bbs2-0002" title="GarlandJS , AlexCP , UhingMR , PetersideIE , RentzA , HarrisMC . Pilot trial to compare tolerance of chlorhexidine gluconate to povidone-iodine antisepsis for central venous catheterplacement in neonates. Journal of Perinatology2009;29(12):808-13. [DOI: 10.1038/jp.2009.161] [PMID: 19812587]GarlandJS . Trial protocol enquiries. Email to: JS Garland 31 March 2021. ">Garland 2009</a> were 304, 114, and 48, respectively; giving a total of 466 neonates.  </p> <p>There were two comparisons:</p> <p> <ul id="CD013841-list-0018"> <li> <p>CHG‐IPA versus PI (<a href="./references#CD013841-bbs2-0002" title="GarlandJS , AlexCP , UhingMR , PetersideIE , RentzA , HarrisMC . Pilot trial to compare tolerance of chlorhexidine gluconate to povidone-iodine antisepsis for central venous catheterplacement in neonates. Journal of Perinatology2009;29(12):808-13. [DOI: 10.1038/jp.2009.161] [PMID: 19812587]GarlandJS . Trial protocol enquiries. Email to: JS Garland 31 March 2021. ">Garland 2009</a>; <a href="./references#CD013841-bbs2-0003" title="EUDRACT 2011-002962-19. Chlorhexidine versus povidone-iodine for skin anitsepsis prior to central venous catheter insertion in preterm infants: protocol for a randomised trial (the SKA trial). clinicaltrialsregister.eu/ctr-search/search?query=2011-002962-19 (first received 4 October 2011). KieranEA , O'SullivanA , MiletinJ , TwomeyAR , KnowlesSJ , O'DonnellCP . 2% chlorhexidine–70% isopropyl alcohol versus10% povidone–iodine for insertion site cleaningbefore central line insertion in preterm infants: a randomised trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2017;103(2):F101-6. [DOI: 10.1136/archdischild-2016-312193] [PMID: 29074717]">Kieran 2018</a>); </p> </li> <li> <p>CHG‐IPA versus CHG‐A (<a href="./references#CD013841-bbs2-0001" title="ClarkeP , CraigJV , WainJ , TremlettC , LinsellL , BowlerU , et al. Safety and efficacy of 2% chlorhexidine gluconate aqueous versus 2% chlorhexidine gluconate in 70% isopropyl alcohol for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: the ARCTIC randomised-controlled feasibility trial protocol. BMJ Open2019;9(2):e028022. [DOI: 10.1136/bmjopen-2018-028022] [PMID: 30782955]ISRCTN82571474. Skin antiseptic trial for insertion of central venous catheters in neonates [The efficacy and safety of two topical antiseptic solutions for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: a feasibility study]. isrctn.com/ISRCTN82571474 (first received 7 July 2016). ">Clarke 2019</a>). </p> </li> </ul> </p> <p>In <a href="./references#CD013841-bbs2-0002" title="GarlandJS , AlexCP , UhingMR , PetersideIE , RentzA , HarrisMC . Pilot trial to compare tolerance of chlorhexidine gluconate to povidone-iodine antisepsis for central venous catheterplacement in neonates. Journal of Perinatology2009;29(12):808-13. [DOI: 10.1038/jp.2009.161] [PMID: 19812587]GarlandJS . Trial protocol enquiries. Email to: JS Garland 31 March 2021. ">Garland 2009</a>, 48 infants from five tertiary NICUs, at seven days of life and above, and weighing 1500 g or more, were randomised to the use of a PI or CHG‐IPA as an antiseptic solution before catheter placement. In <a href="./references#CD013841-bbs2-0003" title="EUDRACT 2011-002962-19. Chlorhexidine versus povidone-iodine for skin anitsepsis prior to central venous catheter insertion in preterm infants: protocol for a randomised trial (the SKA trial). clinicaltrialsregister.eu/ctr-search/search?query=2011-002962-19 (first received 4 October 2011). KieranEA , O'SullivanA , MiletinJ , TwomeyAR , KnowlesSJ , O'DonnellCP . 2% chlorhexidine–70% isopropyl alcohol versus10% povidone–iodine for insertion site cleaningbefore central line insertion in preterm infants: a randomised trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2017;103(2):F101-6. [DOI: 10.1136/archdischild-2016-312193] [PMID: 29074717]">Kieran 2018</a>, the investigators included 304 newborn neonates of less than 31 weeks of gestation from two tertiary hospitals, randomised into either CHG‐IPA or PI. <a href="./references#CD013841-bbs2-0001" title="ClarkeP , CraigJV , WainJ , TremlettC , LinsellL , BowlerU , et al. Safety and efficacy of 2% chlorhexidine gluconate aqueous versus 2% chlorhexidine gluconate in 70% isopropyl alcohol for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: the ARCTIC randomised-controlled feasibility trial protocol. BMJ Open2019;9(2):e028022. [DOI: 10.1136/bmjopen-2018-028022] [PMID: 30782955]ISRCTN82571474. Skin antiseptic trial for insertion of central venous catheters in neonates [The efficacy and safety of two topical antiseptic solutions for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: a feasibility study]. isrctn.com/ISRCTN82571474 (first received 7 July 2016). ">Clarke 2019</a> randomised 114 preterm neonates less than 34 weeks' gestation to the use of either CHG‐IPA or CHG‐A as cutaneous disinfection before central venous catheterisation. In eight neonates the line insertion failed. For these eight, the side effects of chemical burns were reported but CRBSI or other outcomes were not reported. </p> <p>In terms of concomitant antisepsis measures taken, <a href="./references#CD013841-bbs2-0002" title="GarlandJS , AlexCP , UhingMR , PetersideIE , RentzA , HarrisMC . Pilot trial to compare tolerance of chlorhexidine gluconate to povidone-iodine antisepsis for central venous catheterplacement in neonates. Journal of Perinatology2009;29(12):808-13. [DOI: 10.1038/jp.2009.161] [PMID: 19812587]GarlandJS . Trial protocol enquiries. Email to: JS Garland 31 March 2021. ">Garland 2009</a> had the CVC dressing changed weekly, and during each session, the allocated antiseptic solution was reapplied at the catheter insertion site. <a href="./references#CD013841-bbs2-0003" title="EUDRACT 2011-002962-19. Chlorhexidine versus povidone-iodine for skin anitsepsis prior to central venous catheter insertion in preterm infants: protocol for a randomised trial (the SKA trial). clinicaltrialsregister.eu/ctr-search/search?query=2011-002962-19 (first received 4 October 2011). KieranEA , O'SullivanA , MiletinJ , TwomeyAR , KnowlesSJ , O'DonnellCP . 2% chlorhexidine–70% isopropyl alcohol versus10% povidone–iodine for insertion site cleaningbefore central line insertion in preterm infants: a randomised trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2017;103(2):F101-6. [DOI: 10.1136/archdischild-2016-312193] [PMID: 29074717]">Kieran 2018</a> used a sterile transparent dressing that was free from any antiseptic solution. The dressings were not routinely changed, and if changed, sterile saline was used to clean the insertion site before dressing. <a href="./references#CD013841-bbs2-0001" title="ClarkeP , CraigJV , WainJ , TremlettC , LinsellL , BowlerU , et al. Safety and efficacy of 2% chlorhexidine gluconate aqueous versus 2% chlorhexidine gluconate in 70% isopropyl alcohol for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: the ARCTIC randomised-controlled feasibility trial protocol. BMJ Open2019;9(2):e028022. [DOI: 10.1136/bmjopen-2018-028022] [PMID: 30782955]ISRCTN82571474. Skin antiseptic trial for insertion of central venous catheters in neonates [The efficacy and safety of two topical antiseptic solutions for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: a feasibility study]. isrctn.com/ISRCTN82571474 (first received 7 July 2016). ">Clarke 2019</a> did not mention the catheter care bundle used in their trial protocol. We were unable to separate trials with different concomitant antiseptic measures into subgroups, or perform sensitivity analysis to assess the influence of such trials on the overall pooled results due to the small numbers of trials. </p> <p>The outcomes of interest in all three included trials were sepsis, including CRBSI and skin reaction. In addition to that, <a href="./references#CD013841-bbs2-0002" title="GarlandJS , AlexCP , UhingMR , PetersideIE , RentzA , HarrisMC . Pilot trial to compare tolerance of chlorhexidine gluconate to povidone-iodine antisepsis for central venous catheterplacement in neonates. Journal of Perinatology2009;29(12):808-13. [DOI: 10.1038/jp.2009.161] [PMID: 19812587]GarlandJS . Trial protocol enquiries. Email to: JS Garland 31 March 2021. ">Garland 2009</a> and <a href="./references#CD013841-bbs2-0001" title="ClarkeP , CraigJV , WainJ , TremlettC , LinsellL , BowlerU , et al. Safety and efficacy of 2% chlorhexidine gluconate aqueous versus 2% chlorhexidine gluconate in 70% isopropyl alcohol for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: the ARCTIC randomised-controlled feasibility trial protocol. BMJ Open2019;9(2):e028022. [DOI: 10.1136/bmjopen-2018-028022] [PMID: 30782955]ISRCTN82571474. Skin antiseptic trial for insertion of central venous catheters in neonates [The efficacy and safety of two topical antiseptic solutions for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: a feasibility study]. isrctn.com/ISRCTN82571474 (first received 7 July 2016). ">Clarke 2019</a> measured the rate of catheter colonisation as their primary outcome while <a href="./references#CD013841-bbs2-0003" title="EUDRACT 2011-002962-19. Chlorhexidine versus povidone-iodine for skin anitsepsis prior to central venous catheter insertion in preterm infants: protocol for a randomised trial (the SKA trial). clinicaltrialsregister.eu/ctr-search/search?query=2011-002962-19 (first received 4 October 2011). KieranEA , O'SullivanA , MiletinJ , TwomeyAR , KnowlesSJ , O'DonnellCP . 2% chlorhexidine–70% isopropyl alcohol versus10% povidone–iodine for insertion site cleaningbefore central line insertion in preterm infants: a randomised trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2017;103(2):F101-6. [DOI: 10.1136/archdischild-2016-312193] [PMID: 29074717]">Kieran 2018</a> assessed the rate of CRBSI as the primary outcome. Only <a href="./references#CD013841-bbs2-0003" title="EUDRACT 2011-002962-19. Chlorhexidine versus povidone-iodine for skin anitsepsis prior to central venous catheter insertion in preterm infants: protocol for a randomised trial (the SKA trial). clinicaltrialsregister.eu/ctr-search/search?query=2011-002962-19 (first received 4 October 2011). KieranEA , O'SullivanA , MiletinJ , TwomeyAR , KnowlesSJ , O'DonnellCP . 2% chlorhexidine–70% isopropyl alcohol versus10% povidone–iodine for insertion site cleaningbefore central line insertion in preterm infants: a randomised trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2017;103(2):F101-6. [DOI: 10.1136/archdischild-2016-312193] [PMID: 29074717]">Kieran 2018</a> evaluated mortality. The following outcomes were each assessed in only one trial: serum chlorhexidine concentration (<a href="./references#CD013841-bbs2-0002" title="GarlandJS , AlexCP , UhingMR , PetersideIE , RentzA , HarrisMC . Pilot trial to compare tolerance of chlorhexidine gluconate to povidone-iodine antisepsis for central venous catheterplacement in neonates. Journal of Perinatology2009;29(12):808-13. [DOI: 10.1038/jp.2009.161] [PMID: 19812587]GarlandJS . Trial protocol enquiries. Email to: JS Garland 31 March 2021. ">Garland 2009</a>), thyroid dysfunction (<a href="./references#CD013841-bbs2-0003" title="EUDRACT 2011-002962-19. Chlorhexidine versus povidone-iodine for skin anitsepsis prior to central venous catheter insertion in preterm infants: protocol for a randomised trial (the SKA trial). clinicaltrialsregister.eu/ctr-search/search?query=2011-002962-19 (first received 4 October 2011). KieranEA , O'SullivanA , MiletinJ , TwomeyAR , KnowlesSJ , O'DonnellCP . 2% chlorhexidine–70% isopropyl alcohol versus10% povidone–iodine for insertion site cleaningbefore central line insertion in preterm infants: a randomised trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2017;103(2):F101-6. [DOI: 10.1136/archdischild-2016-312193] [PMID: 29074717]">Kieran 2018</a>), and premature catheter removal (<a href="./references#CD013841-bbs2-0001" title="ClarkeP , CraigJV , WainJ , TremlettC , LinsellL , BowlerU , et al. Safety and efficacy of 2% chlorhexidine gluconate aqueous versus 2% chlorhexidine gluconate in 70% isopropyl alcohol for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: the ARCTIC randomised-controlled feasibility trial protocol. BMJ Open2019;9(2):e028022. [DOI: 10.1136/bmjopen-2018-028022] [PMID: 30782955]ISRCTN82571474. Skin antiseptic trial for insertion of central venous catheters in neonates [The efficacy and safety of two topical antiseptic solutions for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: a feasibility study]. isrctn.com/ISRCTN82571474 (first received 7 July 2016). ">Clarke 2019</a>). Even though all included trials evaluated chemical burns, each trial used a different method of assessment. <a href="./references#CD013841-bbs2-0002" title="GarlandJS , AlexCP , UhingMR , PetersideIE , RentzA , HarrisMC . Pilot trial to compare tolerance of chlorhexidine gluconate to povidone-iodine antisepsis for central venous catheterplacement in neonates. Journal of Perinatology2009;29(12):808-13. [DOI: 10.1038/jp.2009.161] [PMID: 19812587]GarlandJS . Trial protocol enquiries. Email to: JS Garland 31 March 2021. ">Garland 2009</a> used contact dermatitis scoring on the scale of 0 to 4; <a href="./references#CD013841-bbs2-0001" title="ClarkeP , CraigJV , WainJ , TremlettC , LinsellL , BowlerU , et al. Safety and efficacy of 2% chlorhexidine gluconate aqueous versus 2% chlorhexidine gluconate in 70% isopropyl alcohol for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: the ARCTIC randomised-controlled feasibility trial protocol. BMJ Open2019;9(2):e028022. [DOI: 10.1136/bmjopen-2018-028022] [PMID: 30782955]ISRCTN82571474. Skin antiseptic trial for insertion of central venous catheters in neonates [The efficacy and safety of two topical antiseptic solutions for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: a feasibility study]. isrctn.com/ISRCTN82571474 (first received 7 July 2016). ">Clarke 2019</a> used a skin morbidity score, a composite score consisting of the level of dryness, erythema, and breakdown; while the method of assessment used in <a href="./references#CD013841-bbs2-0003" title="EUDRACT 2011-002962-19. Chlorhexidine versus povidone-iodine for skin anitsepsis prior to central venous catheter insertion in preterm infants: protocol for a randomised trial (the SKA trial). clinicaltrialsregister.eu/ctr-search/search?query=2011-002962-19 (first received 4 October 2011). KieranEA , O'SullivanA , MiletinJ , TwomeyAR , KnowlesSJ , O'DonnellCP . 2% chlorhexidine–70% isopropyl alcohol versus10% povidone–iodine for insertion site cleaningbefore central line insertion in preterm infants: a randomised trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2017;103(2):F101-6. [DOI: 10.1136/archdischild-2016-312193] [PMID: 29074717]">Kieran 2018</a> was unclear. </p> <p>All trials provided a detailed definition of CRBSI. The definition of CRBSI used in <a href="./references#CD013841-bbs2-0002" title="GarlandJS , AlexCP , UhingMR , PetersideIE , RentzA , HarrisMC . Pilot trial to compare tolerance of chlorhexidine gluconate to povidone-iodine antisepsis for central venous catheterplacement in neonates. Journal of Perinatology2009;29(12):808-13. [DOI: 10.1038/jp.2009.161] [PMID: 19812587]GarlandJS . Trial protocol enquiries. Email to: JS Garland 31 March 2021. ">Garland 2009</a> and <a href="./references#CD013841-bbs2-0001" title="ClarkeP , CraigJV , WainJ , TremlettC , LinsellL , BowlerU , et al. Safety and efficacy of 2% chlorhexidine gluconate aqueous versus 2% chlorhexidine gluconate in 70% isopropyl alcohol for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: the ARCTIC randomised-controlled feasibility trial protocol. BMJ Open2019;9(2):e028022. [DOI: 10.1136/bmjopen-2018-028022] [PMID: 30782955]ISRCTN82571474. Skin antiseptic trial for insertion of central venous catheters in neonates [The efficacy and safety of two topical antiseptic solutions for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: a feasibility study]. isrctn.com/ISRCTN82571474 (first received 7 July 2016). ">Clarke 2019</a> was similar. CRBSI was confirmed if there was a concordant growth of an organism from both culture of the central catheters' part and peripheral blood cultures from an infant with clinical signs of sepsis with an unrecognised focus of infection. <a href="./references#CD013841-bbs2-0002" title="GarlandJS , AlexCP , UhingMR , PetersideIE , RentzA , HarrisMC . Pilot trial to compare tolerance of chlorhexidine gluconate to povidone-iodine antisepsis for central venous catheterplacement in neonates. Journal of Perinatology2009;29(12):808-13. [DOI: 10.1038/jp.2009.161] [PMID: 19812587]GarlandJS . Trial protocol enquiries. Email to: JS Garland 31 March 2021. ">Garland 2009</a> restricted the time point for the outcome assessment from the time of insertion until 24 hours post‐removal of CVC. <a href="./references#CD013841-bbs2-0003" title="EUDRACT 2011-002962-19. Chlorhexidine versus povidone-iodine for skin anitsepsis prior to central venous catheter insertion in preterm infants: protocol for a randomised trial (the SKA trial). clinicaltrialsregister.eu/ctr-search/search?query=2011-002962-19 (first received 4 October 2011). KieranEA , O'SullivanA , MiletinJ , TwomeyAR , KnowlesSJ , O'DonnellCP . 2% chlorhexidine–70% isopropyl alcohol versus10% povidone–iodine for insertion site cleaningbefore central line insertion in preterm infants: a randomised trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2017;103(2):F101-6. [DOI: 10.1136/archdischild-2016-312193] [PMID: 29074717]">Kieran 2018</a> applied a more lenient definition of CRBSI that overlapped with the definition of CLABSI, which did not necessarily require a positive culture of the catheter segment: it was sufficient to have at least a growth of a typical CRBSI‐caused organism in a peripheral blood culture without evidence of related infection at another site. <a href="./references#CD013841-bbs2-0001" title="ClarkeP , CraigJV , WainJ , TremlettC , LinsellL , BowlerU , et al. Safety and efficacy of 2% chlorhexidine gluconate aqueous versus 2% chlorhexidine gluconate in 70% isopropyl alcohol for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: the ARCTIC randomised-controlled feasibility trial protocol. BMJ Open2019;9(2):e028022. [DOI: 10.1136/bmjopen-2018-028022] [PMID: 30782955]ISRCTN82571474. Skin antiseptic trial for insertion of central venous catheters in neonates [The efficacy and safety of two topical antiseptic solutions for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: a feasibility study]. isrctn.com/ISRCTN82571474 (first received 7 July 2016). ">Clarke 2019</a> and <a href="./references#CD013841-bbs2-0002" title="GarlandJS , AlexCP , UhingMR , PetersideIE , RentzA , HarrisMC . Pilot trial to compare tolerance of chlorhexidine gluconate to povidone-iodine antisepsis for central venous catheterplacement in neonates. Journal of Perinatology2009;29(12):808-13. [DOI: 10.1038/jp.2009.161] [PMID: 19812587]GarlandJS . Trial protocol enquiries. Email to: JS Garland 31 March 2021. ">Garland 2009</a> measured CRBSI and CLABSI separately. <a href="./references#CD013841-bbs2-0001" title="ClarkeP , CraigJV , WainJ , TremlettC , LinsellL , BowlerU , et al. Safety and efficacy of 2% chlorhexidine gluconate aqueous versus 2% chlorhexidine gluconate in 70% isopropyl alcohol for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: the ARCTIC randomised-controlled feasibility trial protocol. BMJ Open2019;9(2):e028022. [DOI: 10.1136/bmjopen-2018-028022] [PMID: 30782955]ISRCTN82571474. Skin antiseptic trial for insertion of central venous catheters in neonates [The efficacy and safety of two topical antiseptic solutions for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: a feasibility study]. isrctn.com/ISRCTN82571474 (first received 7 July 2016). ">Clarke 2019</a> used the term catheter‐associated sepsis, while <a href="./references#CD013841-bbs2-0002" title="GarlandJS , AlexCP , UhingMR , PetersideIE , RentzA , HarrisMC . Pilot trial to compare tolerance of chlorhexidine gluconate to povidone-iodine antisepsis for central venous catheterplacement in neonates. Journal of Perinatology2009;29(12):808-13. [DOI: 10.1038/jp.2009.161] [PMID: 19812587]GarlandJS . Trial protocol enquiries. Email to: JS Garland 31 March 2021. ">Garland 2009</a> used the term catheter‐associated bloodstream infection to describe CLABSI; but both trials defined CLABSI similarly. <a href="./references#CD013841-bbs2-0003" title="EUDRACT 2011-002962-19. Chlorhexidine versus povidone-iodine for skin anitsepsis prior to central venous catheter insertion in preterm infants: protocol for a randomised trial (the SKA trial). clinicaltrialsregister.eu/ctr-search/search?query=2011-002962-19 (first received 4 October 2011). KieranEA , O'SullivanA , MiletinJ , TwomeyAR , KnowlesSJ , O'DonnellCP . 2% chlorhexidine–70% isopropyl alcohol versus10% povidone–iodine for insertion site cleaningbefore central line insertion in preterm infants: a randomised trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2017;103(2):F101-6. [DOI: 10.1136/archdischild-2016-312193] [PMID: 29074717]">Kieran 2018</a> did not report the number of CVC tips cultured. All three trials reported the primary outcomes using the number of infants as the units of analysis. </p> </section> <section id="CD013841-sec-0045"> <h4 class="title">Excluded studies</h4> <p>After full‐text assessment, we excluded six articles for the following reasons:</p> <p> <ul id="CD013841-list-0019"> <li> <p>trial design (1 article): article is a review article;</p> </li> <li> <p>intervention (3 articles): the trials focused on antiseptic for peripheral line insertion and umbilical cord separation; </p> </li> <li> <p>trial protocols (2 articles) </p> </li> </ul> </p> <p>A description of each trial is available in the <a href="./references#CD013841-sec-0120" title="">Characteristics of excluded studies</a> tables. </p> </section> <section id="CD013841-sec-0046"> <h4 class="title">Studies awaiting classification</h4> <p>There are no trials awaiting classification.</p> </section> <section id="CD013841-sec-0047"> <h4 class="title">Ongoing studies</h4> <p>We did not identify any ongoing trials.</p> </section> </section> <section id="CD013841-sec-0048"> <h3 class="title">Risk of bias in included studies</h3> <p>All three included trials had overall high risk of bias. <a href="#CD013841-fig-0002">Figure 2</a> shows the proportions of trials with their risks of bias according to each domain, and <a href="#CD013841-fig-0003">Figure 3</a> shows the risk of bias profile according to the trial. Additionally, we have provided a detailed description of the risk of bias of each trial in '<a href="./references#CD013841-sec-0119" title="">Characteristics of included studies</a>' table. Our risk of bias assessment under each domain is summarised below. </p> <div class="figure" id="CD013841-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013841-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_n/nCD013841-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD013841-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013841-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_n/nCD013841-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD013841-sec-0049"> <h4 class="title">Sequence generation</h4> <p>We judged the risk of bias in all included trials to be low: the random sequence generation method was clearly mentioned by the trial authors. The methods used included a secure web‐based facility, computer‐generated block randomisation, and randomisation by an independent researcher. </p> </section> <section id="CD013841-sec-0050"> <h4 class="title">Allocation concealment</h4> <p>We assessed the allocation concealment to be low risk in two included trials (<a href="./references#CD013841-bbs2-0002" title="GarlandJS , AlexCP , UhingMR , PetersideIE , RentzA , HarrisMC . Pilot trial to compare tolerance of chlorhexidine gluconate to povidone-iodine antisepsis for central venous catheterplacement in neonates. Journal of Perinatology2009;29(12):808-13. [DOI: 10.1038/jp.2009.161] [PMID: 19812587]GarlandJS . Trial protocol enquiries. Email to: JS Garland 31 March 2021. ">Garland 2009</a>; <a href="./references#CD013841-bbs2-0003" title="EUDRACT 2011-002962-19. Chlorhexidine versus povidone-iodine for skin anitsepsis prior to central venous catheter insertion in preterm infants: protocol for a randomised trial (the SKA trial). clinicaltrialsregister.eu/ctr-search/search?query=2011-002962-19 (first received 4 October 2011). KieranEA , O'SullivanA , MiletinJ , TwomeyAR , KnowlesSJ , O'DonnellCP . 2% chlorhexidine–70% isopropyl alcohol versus10% povidone–iodine for insertion site cleaningbefore central line insertion in preterm infants: a randomised trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2017;103(2):F101-6. [DOI: 10.1136/archdischild-2016-312193] [PMID: 29074717]">Kieran 2018</a>), but unclear in <a href="./references#CD013841-bbs2-0001" title="ClarkeP , CraigJV , WainJ , TremlettC , LinsellL , BowlerU , et al. Safety and efficacy of 2% chlorhexidine gluconate aqueous versus 2% chlorhexidine gluconate in 70% isopropyl alcohol for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: the ARCTIC randomised-controlled feasibility trial protocol. BMJ Open2019;9(2):e028022. [DOI: 10.1136/bmjopen-2018-028022] [PMID: 30782955]ISRCTN82571474. Skin antiseptic trial for insertion of central venous catheters in neonates [The efficacy and safety of two topical antiseptic solutions for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: a feasibility study]. isrctn.com/ISRCTN82571474 (first received 7 July 2016). ">Clarke 2019</a> as there was insufficient information on the mechanism of allocation. In both <a href="./references#CD013841-bbs2-0002" title="GarlandJS , AlexCP , UhingMR , PetersideIE , RentzA , HarrisMC . Pilot trial to compare tolerance of chlorhexidine gluconate to povidone-iodine antisepsis for central venous catheterplacement in neonates. Journal of Perinatology2009;29(12):808-13. [DOI: 10.1038/jp.2009.161] [PMID: 19812587]GarlandJS . Trial protocol enquiries. Email to: JS Garland 31 March 2021. ">Garland 2009</a> and <a href="./references#CD013841-bbs2-0003" title="EUDRACT 2011-002962-19. Chlorhexidine versus povidone-iodine for skin anitsepsis prior to central venous catheter insertion in preterm infants: protocol for a randomised trial (the SKA trial). clinicaltrialsregister.eu/ctr-search/search?query=2011-002962-19 (first received 4 October 2011). KieranEA , O'SullivanA , MiletinJ , TwomeyAR , KnowlesSJ , O'DonnellCP . 2% chlorhexidine–70% isopropyl alcohol versus10% povidone–iodine for insertion site cleaningbefore central line insertion in preterm infants: a randomised trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2017;103(2):F101-6. [DOI: 10.1136/archdischild-2016-312193] [PMID: 29074717]">Kieran 2018</a>, the trial authors used opaque, sealed, and sequentially numbered envelopes. </p> </section> <section id="CD013841-sec-0051"> <h4 class="title">Blinding</h4> <p>We assessed the blinding of participants and personnel to be at low risk of bias in <a href="./references#CD013841-bbs2-0001" title="ClarkeP , CraigJV , WainJ , TremlettC , LinsellL , BowlerU , et al. Safety and efficacy of 2% chlorhexidine gluconate aqueous versus 2% chlorhexidine gluconate in 70% isopropyl alcohol for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: the ARCTIC randomised-controlled feasibility trial protocol. BMJ Open2019;9(2):e028022. [DOI: 10.1136/bmjopen-2018-028022] [PMID: 30782955]ISRCTN82571474. Skin antiseptic trial for insertion of central venous catheters in neonates [The efficacy and safety of two topical antiseptic solutions for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: a feasibility study]. isrctn.com/ISRCTN82571474 (first received 7 July 2016). ">Clarke 2019</a>, and high risk in <a href="./references#CD013841-bbs2-0002" title="GarlandJS , AlexCP , UhingMR , PetersideIE , RentzA , HarrisMC . Pilot trial to compare tolerance of chlorhexidine gluconate to povidone-iodine antisepsis for central venous catheterplacement in neonates. Journal of Perinatology2009;29(12):808-13. [DOI: 10.1038/jp.2009.161] [PMID: 19812587]GarlandJS . Trial protocol enquiries. Email to: JS Garland 31 March 2021. ">Garland 2009</a> and <a href="./references#CD013841-bbs2-0003" title="EUDRACT 2011-002962-19. Chlorhexidine versus povidone-iodine for skin anitsepsis prior to central venous catheter insertion in preterm infants: protocol for a randomised trial (the SKA trial). clinicaltrialsregister.eu/ctr-search/search?query=2011-002962-19 (first received 4 October 2011). KieranEA , O'SullivanA , MiletinJ , TwomeyAR , KnowlesSJ , O'DonnellCP . 2% chlorhexidine–70% isopropyl alcohol versus10% povidone–iodine for insertion site cleaningbefore central line insertion in preterm infants: a randomised trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2017;103(2):F101-6. [DOI: 10.1136/archdischild-2016-312193] [PMID: 29074717]">Kieran 2018</a>. We rated the risk of bias as high because a lack of blinding of trial personnel may lead to variation in the application of interventions. </p> <p>The risk of detection bias in <a href="./references#CD013841-bbs2-0001" title="ClarkeP , CraigJV , WainJ , TremlettC , LinsellL , BowlerU , et al. Safety and efficacy of 2% chlorhexidine gluconate aqueous versus 2% chlorhexidine gluconate in 70% isopropyl alcohol for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: the ARCTIC randomised-controlled feasibility trial protocol. BMJ Open2019;9(2):e028022. [DOI: 10.1136/bmjopen-2018-028022] [PMID: 30782955]ISRCTN82571474. Skin antiseptic trial for insertion of central venous catheters in neonates [The efficacy and safety of two topical antiseptic solutions for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: a feasibility study]. isrctn.com/ISRCTN82571474 (first received 7 July 2016). ">Clarke 2019</a> was low. Outcome assessors were blinded from the group allocation as the solution used in control and intervention groups were indistinguishable. However, we rated the risk of bias as high in <a href="./references#CD013841-bbs2-0002" title="GarlandJS , AlexCP , UhingMR , PetersideIE , RentzA , HarrisMC . Pilot trial to compare tolerance of chlorhexidine gluconate to povidone-iodine antisepsis for central venous catheterplacement in neonates. Journal of Perinatology2009;29(12):808-13. [DOI: 10.1038/jp.2009.161] [PMID: 19812587]GarlandJS . Trial protocol enquiries. Email to: JS Garland 31 March 2021. ">Garland 2009</a> and <a href="./references#CD013841-bbs2-0003" title="EUDRACT 2011-002962-19. Chlorhexidine versus povidone-iodine for skin anitsepsis prior to central venous catheter insertion in preterm infants: protocol for a randomised trial (the SKA trial). clinicaltrialsregister.eu/ctr-search/search?query=2011-002962-19 (first received 4 October 2011). KieranEA , O'SullivanA , MiletinJ , TwomeyAR , KnowlesSJ , O'DonnellCP . 2% chlorhexidine–70% isopropyl alcohol versus10% povidone–iodine for insertion site cleaningbefore central line insertion in preterm infants: a randomised trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2017;103(2):F101-6. [DOI: 10.1136/archdischild-2016-312193] [PMID: 29074717]">Kieran 2018</a> because some important outcomes such as chemical burns and premature removal of central line were subjective. Knowledge of the intervention received is likely to influence the assessment of outcomes by the care providers. </p> </section> <section id="CD013841-sec-0052"> <h4 class="title">Incomplete outcome data</h4> <p>In <a href="./references#CD013841-bbs2-0002" title="GarlandJS , AlexCP , UhingMR , PetersideIE , RentzA , HarrisMC . Pilot trial to compare tolerance of chlorhexidine gluconate to povidone-iodine antisepsis for central venous catheterplacement in neonates. Journal of Perinatology2009;29(12):808-13. [DOI: 10.1038/jp.2009.161] [PMID: 19812587]GarlandJS . Trial protocol enquiries. Email to: JS Garland 31 March 2021. ">Garland 2009</a> and <a href="./references#CD013841-bbs2-0003" title="EUDRACT 2011-002962-19. Chlorhexidine versus povidone-iodine for skin anitsepsis prior to central venous catheter insertion in preterm infants: protocol for a randomised trial (the SKA trial). clinicaltrialsregister.eu/ctr-search/search?query=2011-002962-19 (first received 4 October 2011). KieranEA , O'SullivanA , MiletinJ , TwomeyAR , KnowlesSJ , O'DonnellCP . 2% chlorhexidine–70% isopropyl alcohol versus10% povidone–iodine for insertion site cleaningbefore central line insertion in preterm infants: a randomised trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2017;103(2):F101-6. [DOI: 10.1136/archdischild-2016-312193] [PMID: 29074717]">Kieran 2018</a>, the risk of bias was low. For <a href="./references#CD013841-bbs2-0001" title="ClarkeP , CraigJV , WainJ , TremlettC , LinsellL , BowlerU , et al. Safety and efficacy of 2% chlorhexidine gluconate aqueous versus 2% chlorhexidine gluconate in 70% isopropyl alcohol for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: the ARCTIC randomised-controlled feasibility trial protocol. BMJ Open2019;9(2):e028022. [DOI: 10.1136/bmjopen-2018-028022] [PMID: 30782955]ISRCTN82571474. Skin antiseptic trial for insertion of central venous catheters in neonates [The efficacy and safety of two topical antiseptic solutions for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: a feasibility study]. isrctn.com/ISRCTN82571474 (first received 7 July 2016). ">Clarke 2019</a>, we judged the risk to be high. The number of missing data for the main outcomes of CRBSI and CLABSI was significant, exceeding the difference in the number of events in both groups. We have contacted the trial author but did not receive a reply, and no information on reasons for missing data was available. Therefore, we assumed that missing data were missing at random. </p> </section> <section id="CD013841-sec-0053"> <h4 class="title">Selective reporting</h4> <p>We judged the risk of bias for selective reporting to be low except in <a href="./references#CD013841-bbs2-0002" title="GarlandJS , AlexCP , UhingMR , PetersideIE , RentzA , HarrisMC . Pilot trial to compare tolerance of chlorhexidine gluconate to povidone-iodine antisepsis for central venous catheterplacement in neonates. Journal of Perinatology2009;29(12):808-13. [DOI: 10.1038/jp.2009.161] [PMID: 19812587]GarlandJS . Trial protocol enquiries. Email to: JS Garland 31 March 2021. ">Garland 2009</a>, which we judged to be unclear as the trial protocol was not available.  </p> </section> <section id="CD013841-sec-0054"> <h4 class="title">Other potential sources of bias</h4> <p>No additional sources of bias were found in all included trials. We intended to use funnel plots to screen for publication bias but were unable to do so because there were insufficient trials (&lt; 10) reporting the same outcome. </p> </section> </section> <section id="CD013841-sec-0055"> <h3 class="title" id="CD013841-sec-0055">Effects of interventions</h3> <p>See: <a href="./full#CD013841-tbl-0001"><b>Summary of findings 1</b> CHG‐IPA versus PI for skin preparation during central‐catheter insertion in neonates</a>; <a href="./full#CD013841-tbl-0002"><b>Summary of findings 2</b> CHG‐IPA versus CHG‐A for skin preparation during central‐catheter insertion in neonates</a> </p> <p>A total of 468 infants were assessed in three trials. We did not identify any significant discrepancies in the characteristics of included trials, and we were able to include the trials in the pooled analysis. There was no trial with multiple comparisons with a common intervention group (a network of intervention), for example between treatment A and B, another between B and C, and the third one between A and D encountered. We included a trial in which the amount of missing data was large enough to cause concern on the direction and magnitude of the effect of the meta‐analysis (<a href="./references#CD013841-bbs2-0001" title="ClarkeP , CraigJV , WainJ , TremlettC , LinsellL , BowlerU , et al. Safety and efficacy of 2% chlorhexidine gluconate aqueous versus 2% chlorhexidine gluconate in 70% isopropyl alcohol for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: the ARCTIC randomised-controlled feasibility trial protocol. BMJ Open2019;9(2):e028022. [DOI: 10.1136/bmjopen-2018-028022] [PMID: 30782955]ISRCTN82571474. Skin antiseptic trial for insertion of central venous catheters in neonates [The efficacy and safety of two topical antiseptic solutions for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: a feasibility study]. isrctn.com/ISRCTN82571474 (first received 7 July 2016). ">Clarke 2019</a>); however, we were unable to perform sensitivity analysis because there was only a single trial included in the particular comparison. We addressed the potential impact of missing data on the findings of the review in the <a href="#CD013841-sec-0090">Discussion</a> section. There was no meta‐analysis with a moderate or large degree of heterogeneity and no continuous data available for analysis. </p> <section id="CD013841-sec-0056"> <h4 class="title">Comparison 1: CHG‐IPA versus PI</h4> <p>The pooled effect estimates of the most important outcomes, which include both primary and few secondary outcomes, under this comparison with their certainty of evidence are tabulated in <a href="./full#CD013841-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD013841-sec-0057"> <h5 class="title">Primary outcomes</h5> <section id="CD013841-sec-0058"> <h6 class="title">Proven CRBSI (Analysis 1.1)</h6> <p>Two trials reported this outcome (<a href="./references#CD013841-bbs2-0002" title="GarlandJS , AlexCP , UhingMR , PetersideIE , RentzA , HarrisMC . Pilot trial to compare tolerance of chlorhexidine gluconate to povidone-iodine antisepsis for central venous catheterplacement in neonates. Journal of Perinatology2009;29(12):808-13. [DOI: 10.1038/jp.2009.161] [PMID: 19812587]GarlandJS . Trial protocol enquiries. Email to: JS Garland 31 March 2021. ">Garland 2009</a>; <a href="./references#CD013841-bbs2-0003" title="EUDRACT 2011-002962-19. Chlorhexidine versus povidone-iodine for skin anitsepsis prior to central venous catheter insertion in preterm infants: protocol for a randomised trial (the SKA trial). clinicaltrialsregister.eu/ctr-search/search?query=2011-002962-19 (first received 4 October 2011). KieranEA , O'SullivanA , MiletinJ , TwomeyAR , KnowlesSJ , O'DonnellCP . 2% chlorhexidine–70% isopropyl alcohol versus10% povidone–iodine for insertion site cleaningbefore central line insertion in preterm infants: a randomised trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2017;103(2):F101-6. [DOI: 10.1136/archdischild-2016-312193] [PMID: 29074717]">Kieran 2018</a>). However, one trial had no positive outcome in both group. One trial used CRBSI definition that overlapped with CLABSI (<a href="./references#CD013841-bbs2-0003" title="EUDRACT 2011-002962-19. Chlorhexidine versus povidone-iodine for skin anitsepsis prior to central venous catheter insertion in preterm infants: protocol for a randomised trial (the SKA trial). clinicaltrialsregister.eu/ctr-search/search?query=2011-002962-19 (first received 4 October 2011). KieranEA , O'SullivanA , MiletinJ , TwomeyAR , KnowlesSJ , O'DonnellCP . 2% chlorhexidine–70% isopropyl alcohol versus10% povidone–iodine for insertion site cleaningbefore central line insertion in preterm infants: a randomised trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2017;103(2):F101-6. [DOI: 10.1136/archdischild-2016-312193] [PMID: 29074717]">Kieran 2018</a>). However, we did not perform sensitivity analysis as this was the only trial that have positive findings for this outcome. CHG‐IPA may result in little to no difference in CRBSI  (risk ratio (RR) 1.32, 95% confidence intervals (CI) 0.53 to 3.25; RD 0.01, 95% CI −0.03 to 0.06; 352 infants, I² = 0%; low‐certainty evidence; <a href="./references#CD013841-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD013841-sec-0059"> <h6 class="title">CLABSI (Analysis 1.2) </h6> <p>Based on the findings of a single trial (<a href="./references#CD013841-bbs2-0002" title="GarlandJS , AlexCP , UhingMR , PetersideIE , RentzA , HarrisMC . Pilot trial to compare tolerance of chlorhexidine gluconate to povidone-iodine antisepsis for central venous catheterplacement in neonates. Journal of Perinatology2009;29(12):808-13. [DOI: 10.1038/jp.2009.161] [PMID: 19812587]GarlandJS . Trial protocol enquiries. Email to: JS Garland 31 March 2021. ">Garland 2009</a>), the evidence is very uncertain about the effect of CHG‐IPA on CLABSI (RR 1.00, 95% CI 0.07 to 15.08; RD 0.00, 95% CI −0.11 to 0.11; 48 infants; very low‐certainty evidence; <a href="./references#CD013841-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD013841-sec-0060"> <h6 class="title">Probable sepsis (Analysis 1.3)</h6> <p>We included trials that used different terms with similar meanings such as "presumed bloodstream infection" (<a href="./references#CD013841-bbs2-0002" title="GarlandJS , AlexCP , UhingMR , PetersideIE , RentzA , HarrisMC . Pilot trial to compare tolerance of chlorhexidine gluconate to povidone-iodine antisepsis for central venous catheterplacement in neonates. Journal of Perinatology2009;29(12):808-13. [DOI: 10.1038/jp.2009.161] [PMID: 19812587]GarlandJS . Trial protocol enquiries. Email to: JS Garland 31 March 2021. ">Garland 2009</a>), and "suspected sepsis" (<a href="./references#CD013841-bbs2-0003" title="EUDRACT 2011-002962-19. Chlorhexidine versus povidone-iodine for skin anitsepsis prior to central venous catheter insertion in preterm infants: protocol for a randomised trial (the SKA trial). clinicaltrialsregister.eu/ctr-search/search?query=2011-002962-19 (first received 4 October 2011). KieranEA , O'SullivanA , MiletinJ , TwomeyAR , KnowlesSJ , O'DonnellCP . 2% chlorhexidine–70% isopropyl alcohol versus10% povidone–iodine for insertion site cleaningbefore central line insertion in preterm infants: a randomised trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2017;103(2):F101-6. [DOI: 10.1136/archdischild-2016-312193] [PMID: 29074717]">Kieran 2018</a>). We did not perform sensitivity analysis as we found no conflicting definitions employed by the authors of these trials. Based on the findings of two trials (<a href="./references#CD013841-bbs2-0002" title="GarlandJS , AlexCP , UhingMR , PetersideIE , RentzA , HarrisMC . Pilot trial to compare tolerance of chlorhexidine gluconate to povidone-iodine antisepsis for central venous catheterplacement in neonates. Journal of Perinatology2009;29(12):808-13. [DOI: 10.1038/jp.2009.161] [PMID: 19812587]GarlandJS . Trial protocol enquiries. Email to: JS Garland 31 March 2021. ">Garland 2009</a>; <a href="./references#CD013841-bbs2-0003" title="EUDRACT 2011-002962-19. Chlorhexidine versus povidone-iodine for skin anitsepsis prior to central venous catheter insertion in preterm infants: protocol for a randomised trial (the SKA trial). clinicaltrialsregister.eu/ctr-search/search?query=2011-002962-19 (first received 4 October 2011). KieranEA , O'SullivanA , MiletinJ , TwomeyAR , KnowlesSJ , O'DonnellCP . 2% chlorhexidine–70% isopropyl alcohol versus10% povidone–iodine for insertion site cleaningbefore central line insertion in preterm infants: a randomised trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2017;103(2):F101-6. [DOI: 10.1136/archdischild-2016-312193] [PMID: 29074717]">Kieran 2018</a>), there was no significant difference between the two groups in probable sepsis (RR 1.11, 95% CI 0.58 to 2.11; RD 0.01, 95% CI −0.05 to 0.07; 352 infants; <a href="./references#CD013841-fig-0006" title="">Analysis 1.3</a>). </p> </section> <section id="CD013841-sec-0061"> <h6 class="title">All‐cause mortality (Analysis 1.4)</h6> <p>Based on the findings of a single trial (<a href="./references#CD013841-bbs2-0003" title="EUDRACT 2011-002962-19. Chlorhexidine versus povidone-iodine for skin anitsepsis prior to central venous catheter insertion in preterm infants: protocol for a randomised trial (the SKA trial). clinicaltrialsregister.eu/ctr-search/search?query=2011-002962-19 (first received 4 October 2011). KieranEA , O'SullivanA , MiletinJ , TwomeyAR , KnowlesSJ , O'DonnellCP . 2% chlorhexidine–70% isopropyl alcohol versus10% povidone–iodine for insertion site cleaningbefore central line insertion in preterm infants: a randomised trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2017;103(2):F101-6. [DOI: 10.1136/archdischild-2016-312193] [PMID: 29074717]">Kieran 2018</a>), CHG‐IPA may result in little to no difference in all‐cause mortality (RR 0.88, 95% CI 0.46 to 1.68; RD −0.01, 95% CI −0.08 to 0.06; 304 infants; low‐certainty evidence; <a href="./references#CD013841-fig-0007" title="">Analysis 1.4</a>). </p> </section> <section id="CD013841-sec-0062"> <h6 class="title">Chemical burns (Analysis 1.5)</h6> <p>Based on the findings of two trials (<a href="./references#CD013841-bbs2-0002" title="GarlandJS , AlexCP , UhingMR , PetersideIE , RentzA , HarrisMC . Pilot trial to compare tolerance of chlorhexidine gluconate to povidone-iodine antisepsis for central venous catheterplacement in neonates. Journal of Perinatology2009;29(12):808-13. [DOI: 10.1038/jp.2009.161] [PMID: 19812587]GarlandJS . Trial protocol enquiries. Email to: JS Garland 31 March 2021. ">Garland 2009</a>; <a href="./references#CD013841-bbs2-0003" title="EUDRACT 2011-002962-19. Chlorhexidine versus povidone-iodine for skin anitsepsis prior to central venous catheter insertion in preterm infants: protocol for a randomised trial (the SKA trial). clinicaltrialsregister.eu/ctr-search/search?query=2011-002962-19 (first received 4 October 2011). KieranEA , O'SullivanA , MiletinJ , TwomeyAR , KnowlesSJ , O'DonnellCP . 2% chlorhexidine–70% isopropyl alcohol versus10% povidone–iodine for insertion site cleaningbefore central line insertion in preterm infants: a randomised trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2017;103(2):F101-6. [DOI: 10.1136/archdischild-2016-312193] [PMID: 29074717]">Kieran 2018</a>), CHG‐IPA may have little to no effect on chemical burn, but the evidence is very uncertain (RR 1.04, 95% CI 0.24 to 4.48; RD 0.00, 95% CI −0.03 to 0.03; 352 infants, I² = 0%; very low‐certainty evidence; <a href="./references#CD013841-fig-0008" title="">Analysis 1.5</a>). </p> </section> </section> <section id="CD013841-sec-0063"> <h5 class="title">Secondary outcomes</h5> <section id="CD013841-sec-0064"> <h6 class="title">Catheter colonisation (Analysis 1.6)</h6> <p>Based on the findings of one small trial (<a href="./references#CD013841-bbs2-0002" title="GarlandJS , AlexCP , UhingMR , PetersideIE , RentzA , HarrisMC . Pilot trial to compare tolerance of chlorhexidine gluconate to povidone-iodine antisepsis for central venous catheterplacement in neonates. Journal of Perinatology2009;29(12):808-13. [DOI: 10.1038/jp.2009.161] [PMID: 19812587]GarlandJS . Trial protocol enquiries. Email to: JS Garland 31 March 2021. ">Garland 2009</a>), there was no significant difference between the two groups in catheter colonisation (RR 3.00, 95% CI 0.34 to 26.84; RD 0.08, 95% CI −0.07 to 0.24; 48 infants; <a href="./references#CD013841-fig-0009" title="">Analysis 1.6</a>). </p> </section> <section id="CD013841-sec-0065"> <h6 class="title">Premature catheter removal</h6> <p>No data from included trials.</p> </section> <section id="CD013841-sec-0066"> <h6 class="title">Exit site infection</h6> <p>No data from included trials.</p> </section> <section id="CD013841-sec-0067"> <h6 class="title">The proportion of infants with antiseptic‐resistant organisms from cultures</h6> <p>No data from included trials.</p> </section> <section id="CD013841-sec-0068"> <h6 class="title">Antibiotic usage throughout catheter in‐dwelling time (proportion of infant/ duration of antibiotics) </h6> <p>No data from included trials.</p> </section> <section id="CD013841-sec-0069"> <h6 class="title">Length of hospitalisation</h6> <p>No data from included trials.</p> </section> <section id="CD013841-sec-0070"> <h6 class="title">Thyroid dysfunction (Analysis 1.7)</h6> <p>A single trial (<a href="./references#CD013841-bbs2-0003" title="EUDRACT 2011-002962-19. Chlorhexidine versus povidone-iodine for skin anitsepsis prior to central venous catheter insertion in preterm infants: protocol for a randomised trial (the SKA trial). clinicaltrialsregister.eu/ctr-search/search?query=2011-002962-19 (first received 4 October 2011). KieranEA , O'SullivanA , MiletinJ , TwomeyAR , KnowlesSJ , O'DonnellCP . 2% chlorhexidine–70% isopropyl alcohol versus10% povidone–iodine for insertion site cleaningbefore central line insertion in preterm infants: a randomised trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2017;103(2):F101-6. [DOI: 10.1136/archdischild-2016-312193] [PMID: 29074717]">Kieran 2018</a>), showed that infants who received chlorhexidine in alcohol were significantly less likely to develop thyroid dysfunction compared to infants who received povidone iodine (RR 0.05, 95% CI 0.00 to 0.85; RD −0.06, 95% CI −0.10 to ‐0.02; NNTH 17, 95% CI 10 to 50; 304 infants; <a href="./references#CD013841-fig-0010" title="">Analysis 1.7</a>). </p> </section> <section id="CD013841-sec-0071"> <h6 class="title">Allergy and anaphylaxis</h6> <p>No data from included trials.</p> </section> <section id="CD013841-sec-0072"> <h6 class="title">Neurodevelopmental outcome</h6> <p>No data from included trials.</p> </section> </section> </section> <section id="CD013841-sec-0073"> <h4 class="title">Comparison 2: CHG‐IPA versus CHG‐A</h4> <p>A single trial reported on this comparison (<a href="./references#CD013841-bbs2-0001" title="ClarkeP , CraigJV , WainJ , TremlettC , LinsellL , BowlerU , et al. Safety and efficacy of 2% chlorhexidine gluconate aqueous versus 2% chlorhexidine gluconate in 70% isopropyl alcohol for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: the ARCTIC randomised-controlled feasibility trial protocol. BMJ Open2019;9(2):e028022. [DOI: 10.1136/bmjopen-2018-028022] [PMID: 30782955]ISRCTN82571474. Skin antiseptic trial for insertion of central venous catheters in neonates [The efficacy and safety of two topical antiseptic solutions for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: a feasibility study]. isrctn.com/ISRCTN82571474 (first received 7 July 2016). ">Clarke 2019</a>). </p> <p>The pooled effect estimates of most important outcomes that include both primary and few secondary outcomes under this comparison with their certainty of evidence is tabulated in <a href="./full#CD013841-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD013841-sec-0074"> <h5 class="title">Primary outcomes</h5> <section id="CD013841-sec-0075"> <h6 class="title">Proven CRBSI (Analysis 2.1)</h6> <p>The evidence suggests CHG‐IPA may result in little to no difference in the rate of proven CRBSI when applied on the skin of neonates prior to central line insertion (RR 0.80, 95% CI 0.34 to 1.87; RD −0.05, 95% CI −0.22 to 0.13; 106 infants; low‐certainty evidence; <a href="./references#CD013841-fig-0011" title="">Analysis 2.1</a>). </p> </section> <section id="CD013841-sec-0076"> <h6 class="title">CLABSI (Analysis 2.2)</h6> <p>The evidence suggests CHG‐IPA may result in little to no difference in the rate of CLABSI compared to CHG‐A (RR 1.14, 95% CI 0.34 to 3.84; RD 0.02, 95% CI −0.12 to 0.15; 106 infants; low‐certainty evidence; <a href="./references#CD013841-fig-0012" title="">Analysis 2.2</a>). </p> </section> <section id="CD013841-sec-0077"> <h6 class="title">Probable sepsis </h6> <p>No data from the included trial.</p> </section> <section id="CD013841-sec-0078"> <h6 class="title">All‐cause mortality</h6> <p>No data from the included trial.</p> </section> <section id="CD013841-sec-0079"> <h6 class="title">Chemical burns (Analysis 2.3)</h6> <p>Compared to CHG‐A, CHG‐IPA probably results in little to no difference in chemical burns (RR 0.98, 95% CI 0.47 to 2.03; RD −0.01, 95% CI −0.20 to 0.18; 114 infants; moderate‐certainty evidence; <a href="./references#CD013841-fig-0013" title="">Analysis 2.3</a>). </p> </section> </section> <section id="CD013841-sec-0080"> <h5 class="title">Secondary outcomes</h5> <section id="CD013841-sec-0081"> <h6 class="title">Catheter colonisation (Analysis 2.4)</h6> <p>There was no difference in the rate of catheter colonisation between the group that received chlorhexidine in alcohol and the one that received CHG‐A (RR 0.51, 95% CI 0.09 to 2.91; RD −0.04, 95% CI −0.14 to 0.07; 106 infants; <a href="./references#CD013841-fig-0014" title="">Analysis 2.4</a>). </p> </section> <section id="CD013841-sec-0082"> <h6 class="title">Premature catheter removal (Analysis 2.5)</h6> <p>CHG‐IPA probably results in little to no difference in premature central line removal (RR 0.91, 95% CI 0.26 to 3.19; RD −0.01, 95% CI −0.15 to 0.13; 106 infants: moderate‐certainty evidence; <a href="./references#CD013841-fig-0015" title="">Analysis 2.5</a>). </p> </section> <section id="CD013841-sec-0083"> <h6 class="title">Exit site infection</h6> <p>No data from the included trial.</p> </section> <section id="CD013841-sec-0084"> <h6 class="title">The proportion of infants with antiseptic‐resistant organisms from cultures</h6> <p>No data from the included trial.</p> </section> <section id="CD013841-sec-0085"> <h6 class="title">Antibiotic usage throughout catheter in‐dwelling time (proportion of infant/ duration of antibiotics) </h6> <p>No data from the included trial.</p> </section> <section id="CD013841-sec-0086"> <h6 class="title">Length of hospitalisation</h6> <p>No data from the included trial.</p> </section> <section id="CD013841-sec-0087"> <h6 class="title">Thyroid dysfunction</h6> <p>No data from the included trial.</p> </section> <section id="CD013841-sec-0088"> <h6 class="title">Allergy and anaphylaxis</h6> <p>No data from the included trial.</p> </section> <section id="CD013841-sec-0089"> <h6 class="title">Neurodevelopmental outcome</h6> <p>No data from the included trial.</p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013841-sec-0090" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013841-sec-0090"></div> <section id="CD013841-sec-0091"> <h3 class="title" id="CD013841-sec-0091">Summary of main results</h3> <p>Three trials, including 466 neonates met the inclusion criteria of this Cochrane Review. Three antiseptic solutions were evaluated during central catheter insertion in neonates: CHG‐IPA, CHG‐A, and PI. </p> <p>Two trials comparing CHG‐IPA versus PI reported four of the prespecified primary outcomes (<a href="./references#CD013841-bbs2-0002" title="GarlandJS , AlexCP , UhingMR , PetersideIE , RentzA , HarrisMC . Pilot trial to compare tolerance of chlorhexidine gluconate to povidone-iodine antisepsis for central venous catheterplacement in neonates. Journal of Perinatology2009;29(12):808-13. [DOI: 10.1038/jp.2009.161] [PMID: 19812587]GarlandJS . Trial protocol enquiries. Email to: JS Garland 31 March 2021. ">Garland 2009</a>; <a href="./references#CD013841-bbs2-0003" title="EUDRACT 2011-002962-19. Chlorhexidine versus povidone-iodine for skin anitsepsis prior to central venous catheter insertion in preterm infants: protocol for a randomised trial (the SKA trial). clinicaltrialsregister.eu/ctr-search/search?query=2011-002962-19 (first received 4 October 2011). KieranEA , O'SullivanA , MiletinJ , TwomeyAR , KnowlesSJ , O'DonnellCP . 2% chlorhexidine–70% isopropyl alcohol versus10% povidone–iodine for insertion site cleaningbefore central line insertion in preterm infants: a randomised trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2017;103(2):F101-6. [DOI: 10.1136/archdischild-2016-312193] [PMID: 29074717]">Kieran 2018</a>). Overall mortality was only reported in one trial (<a href="./references#CD013841-bbs2-0003" title="EUDRACT 2011-002962-19. Chlorhexidine versus povidone-iodine for skin anitsepsis prior to central venous catheter insertion in preterm infants: protocol for a randomised trial (the SKA trial). clinicaltrialsregister.eu/ctr-search/search?query=2011-002962-19 (first received 4 October 2011). KieranEA , O'SullivanA , MiletinJ , TwomeyAR , KnowlesSJ , O'DonnellCP . 2% chlorhexidine–70% isopropyl alcohol versus10% povidone–iodine for insertion site cleaningbefore central line insertion in preterm infants: a randomised trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2017;103(2):F101-6. [DOI: 10.1136/archdischild-2016-312193] [PMID: 29074717]">Kieran 2018</a>). CHG‐IPA may result in little to no difference in CRBSI and mortality. CHG‐IPA may have little to no effect on CLABSI and chemical burns, but the evidence is very uncertain. One trial reported no difference in catheter colonisation (<a href="./references#CD013841-bbs2-0002" title="GarlandJS , AlexCP , UhingMR , PetersideIE , RentzA , HarrisMC . Pilot trial to compare tolerance of chlorhexidine gluconate to povidone-iodine antisepsis for central venous catheterplacement in neonates. Journal of Perinatology2009;29(12):808-13. [DOI: 10.1038/jp.2009.161] [PMID: 19812587]GarlandJS . Trial protocol enquiries. Email to: JS Garland 31 March 2021. ">Garland 2009</a>), and one trial reported a significantly higher incidence of thyroid dysfunction in the PI group (<a href="./references#CD013841-bbs2-0003" title="EUDRACT 2011-002962-19. Chlorhexidine versus povidone-iodine for skin anitsepsis prior to central venous catheter insertion in preterm infants: protocol for a randomised trial (the SKA trial). clinicaltrialsregister.eu/ctr-search/search?query=2011-002962-19 (first received 4 October 2011). KieranEA , O'SullivanA , MiletinJ , TwomeyAR , KnowlesSJ , O'DonnellCP . 2% chlorhexidine–70% isopropyl alcohol versus10% povidone–iodine for insertion site cleaningbefore central line insertion in preterm infants: a randomised trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2017;103(2):F101-6. [DOI: 10.1136/archdischild-2016-312193] [PMID: 29074717]">Kieran 2018</a>). Other prespecified secondary outcomes were not reported. </p> <p>One trial compared CHG‐IPA versus CHG‐A (<a href="./references#CD013841-bbs2-0001" title="ClarkeP , CraigJV , WainJ , TremlettC , LinsellL , BowlerU , et al. Safety and efficacy of 2% chlorhexidine gluconate aqueous versus 2% chlorhexidine gluconate in 70% isopropyl alcohol for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: the ARCTIC randomised-controlled feasibility trial protocol. BMJ Open2019;9(2):e028022. [DOI: 10.1136/bmjopen-2018-028022] [PMID: 30782955]ISRCTN82571474. Skin antiseptic trial for insertion of central venous catheters in neonates [The efficacy and safety of two topical antiseptic solutions for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: a feasibility study]. isrctn.com/ISRCTN82571474 (first received 7 July 2016). ">Clarke 2019</a>). The evidence suggests CHG‐IPA may result in little to no difference in the rate of proven CRBSI and CLABSI, and probably results in little to no difference in chemical burns and premature catheter removal when applied on the skin of neonates prior to central line insertion. </p> </section> <section id="CD013841-sec-0092"> <h3 class="title" id="CD013841-sec-0092">Overall completeness and applicability of evidence</h3> <p>We believe the included trials, although small, represented the best available evidence at the time of the review to answer the questions that we posed in conducting this review. A total of 458 neonates were assessed. Comparisons of antiseptic solutions were limited in number. All trials were conducted in high‐income countries; one in the USA, one in the UK, and one in Ireland. It is uncertain whether the results of this review can be extrapolated to settings in low‐ and middle‐income countries. </p> <p>The inclusion criteria adopted by each trial were different. One trial recruited infants more than 1500 g, while the other two trials used gestational age as the inclusion criteria (one less than 34 weeks and the other less than 31 weeks). Two trials included in the meta‐analysis had different mean gestational ages, 32.7 ± 3.6 and 27 ± 2.0. However, the meta‐analysis showed low heterogeneity (I<sup>2</sup> = 0%). We were unable to undertake any subgroup analysis to determine further applicability of the findings to infants with different prognostic factors, such as different gestational ages and weight, due to insufficient data. </p> <p>Furthermore, the included trials employed different central catheter care policies for insertion and maintenance of central line. These differences in local practices may have influenced the outcomes and affected the result of our meta‐analyses. For instance, one trial practised weekly change of catheter dressing and reapplied the same allocated antiseptic solution during each dressing change (<a href="./references#CD013841-bbs2-0002" title="GarlandJS , AlexCP , UhingMR , PetersideIE , RentzA , HarrisMC . Pilot trial to compare tolerance of chlorhexidine gluconate to povidone-iodine antisepsis for central venous catheterplacement in neonates. Journal of Perinatology2009;29(12):808-13. [DOI: 10.1038/jp.2009.161] [PMID: 19812587]GarlandJS . Trial protocol enquiries. Email to: JS Garland 31 March 2021. ">Garland 2009</a>). This could explain the lack of incidence of CRBSI in both the case and control groups in the trial. In <a href="./references#CD013841-bbs2-0003" title="EUDRACT 2011-002962-19. Chlorhexidine versus povidone-iodine for skin anitsepsis prior to central venous catheter insertion in preterm infants: protocol for a randomised trial (the SKA trial). clinicaltrialsregister.eu/ctr-search/search?query=2011-002962-19 (first received 4 October 2011). KieranEA , O'SullivanA , MiletinJ , TwomeyAR , KnowlesSJ , O'DonnellCP . 2% chlorhexidine–70% isopropyl alcohol versus10% povidone–iodine for insertion site cleaningbefore central line insertion in preterm infants: a randomised trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2017;103(2):F101-6. [DOI: 10.1136/archdischild-2016-312193] [PMID: 29074717]">Kieran 2018</a>, the trial investigators allowed clinicians who performed the intervention to decide on the method of securing UVCs i.e. either using sterile dressing or not. Furthermore, sterile water was used to clean the catheter insertion site during changing of dressing.  </p> </section> <section id="CD013841-sec-0093"> <h3 class="title" id="CD013841-sec-0093">Certainty of the evidence</h3> <p>Overall, the small number of included trials provided very low‐ to moderate‐certainty evidence (<a href="./full#CD013841-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD013841-tbl-0002">summary of findings Table 2</a>). The included trials were at high risk of bias. We downgraded the certainty of the evidence due to imprecision for all the outcomes, owing to the wide CIs. The certainty of the evidence was further reduced due to the high risk of bias, particularly in the blinding of the outcome assessor.  </p> </section> <section id="CD013841-sec-0094"> <h3 class="title" id="CD013841-sec-0094">Potential biases in the review process</h3> <p>We did not search Embase independently and realise this may have reduced the sensitivity of our literature search due to the time lag between Embase records being added to Cochrane CENTRAL. Two trials included in the meta‐analysis involved different neonatal populations, and although the effect estimates between the trials were similar, our decision to pool them may be subject to debate. The limited number of included trials prevented us from performing subgroup or sensitivity analysis.  </p> <p>One of the major limitations in this review is the use of different post catheter insertion care and antisepsis bundle in each trial, such as changing of dressing and reapplication of antiseptic solution during dressing amongst different trials. This might have affected the actual numbers of events for some of the efficacy outcomes, such as CRBSI and CLABSI. We initially planned to exclude trials where reapplication of the antiseptic solution was done; however, at review stage, we included a trial that performed reapplication of the antiseptic solution as it was done in both trial arms (<a href="./references#CD013841-bbs2-0002" title="GarlandJS , AlexCP , UhingMR , PetersideIE , RentzA , HarrisMC . Pilot trial to compare tolerance of chlorhexidine gluconate to povidone-iodine antisepsis for central venous catheterplacement in neonates. Journal of Perinatology2009;29(12):808-13. [DOI: 10.1038/jp.2009.161] [PMID: 19812587]GarlandJS . Trial protocol enquiries. Email to: JS Garland 31 March 2021. ">Garland 2009</a>). This deviation in the protocol after assessing the trial represented another limitation of this review.  </p> <p>The trial that compared CHG‐IPA versus CHG‐A was described individually with no meta‐analysis possible. We were unable to perform sensitivity analysis to examine the impact of our decision on the direction and magnitude of the pooled estimate as only one trial was available for this comparison. This decision may introduce bias in the review process.  </p> <p>Two trials included in the meta‐analysis for the outcome of chemical burn applied different methods of outcome assessments. The inclusion of these two trials may potentially introduce bias. However, we could not perform sensitivity analysis in view of small number of included trials.  </p> <p>We included a new primary outcome and rearranged the outcomes post‐hoc after discussion amongst the review authors, as this new outcome was considered an important outcome that we had not considered at the protocol stage. </p> </section> <section id="CD013841-sec-0095"> <h3 class="title" id="CD013841-sec-0095">Agreements and disagreements with other studies or reviews</h3> <p><a href="./references#CD013841-bbs2-0010" title="BagheriI , FallahB , DadgariA , FarahaniAS , SalmaniN . A literature review of selection of appropriate antiseptics when inserting intravenous catheters in premature infants: the challenge in neonatal intensive care unit. Journal of Clinical Neonatology2020;9(3):162-7. [DOI: 10.4103/jcn.JCN_135_19]">Bagheri 2020</a> did a literature review of trials that compare different types of skin antiseptic solutions in neonates. Similarly, the author only found three trials that compared different types of antiseptic solutions in neonates. The authors claimed that there are no guidelines available to guide the clinician on the criteria to consider before choosing a specific antiseptic solution before invasive procedures in preterm infants. </p> <p><a href="./references#CD013841-bbs2-0050" title="PonnusamyV , VenkateshV , ClarkeP . Skin antisepsis in the neonate: what should we use?Current Opinion in Infectious Diseases2014;27(3):244-50. [DOI: 10.1097/QCO.0000000000000064] [PMID: 24751895]">Ponnusamy 2014</a>, in their review of topical antiseptic used in neonates, found no clinical trials that investigate the safety and efficacy of skin antiseptic solutions in infants before CVC insertion. One large RCT compared the effect of applying either 70% isopropyl alcohol or PI followed by the use of 70% isopropyl alcohol/chlorhexidine‐impregnated dressing. In that trial, the use of alcohol reduced the incidence of catheter colonisation without affecting the rate of CRBSI or CLABSI. However, due to limited evidence, no recommendation on the choice of antiseptic solution could be made. </p> <p><a href="./references#CD013841-bbs2-0052" title="SathiyamurthyS , BanerjeeJ , GodambeSV . Antiseptic use in the neonatal intensive care unit - a dilemma in clinical practice: an evidence based review. World Journal of Clinical Pediatrics2016;5(2):159-71. [DOI: 10.5409/wjcp.v5.i2.159] [PMID: 27170926]">Sathiyamurthy 2016</a> conducted a broad review on the antiseptics used in the NICU. In the analysis of antiseptics used for central catheter insertion, the authors included only one clinical trial and concluded that both chlorhexidine in alcohol and PI have similar efficacy in preventing CRBSI. However, the use of PI predisposed to thyroid dysfunction. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013841-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/urn:x-wiley:14651858:media:CD013841:CD013841-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD013841-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_n/nCD013841-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_t/tCD013841-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/full#CD013841-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_n/nCD013841-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013841-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/urn:x-wiley:14651858:media:CD013841:CD013841-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013841-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_n/nCD013841-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_t/tCD013841-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/full#CD013841-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_n/nCD013841-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013841-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/urn:x-wiley:14651858:media:CD013841:CD013841-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013841-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_n/nCD013841-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_t/tCD013841-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/full#CD013841-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_n/nCD013841-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013841-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/urn:x-wiley:14651858:media:CD013841:CD013841-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: 2% chlorhexidine‐70% isopropyl (CHG‐IPA) versus 10% povidone‐iodine (PI), Outcome 1: Proven catheter‐related blood stream infection (CRBSI)" data-id="CD013841-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_n/nCD013841-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_t/tCD013841-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: 2% chlorhexidine‐70% isopropyl (CHG‐IPA) versus 10% povidone‐iodine (PI), Outcome 1: Proven catheter‐related blood stream infection (CRBSI) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/references#CD013841-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_n/nCD013841-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013841-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/urn:x-wiley:14651858:media:CD013841:CD013841-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: 2% chlorhexidine‐70% isopropyl (CHG‐IPA) versus 10% povidone‐iodine (PI), Outcome 2: Central‐line associated bloodstream infection (CLABSI)" data-id="CD013841-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_n/nCD013841-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_t/tCD013841-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: 2% chlorhexidine‐70% isopropyl (CHG‐IPA) versus 10% povidone‐iodine (PI), Outcome 2: Central‐line associated bloodstream infection (CLABSI) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/references#CD013841-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_n/nCD013841-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013841-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/urn:x-wiley:14651858:media:CD013841:CD013841-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: 2% chlorhexidine‐70% isopropyl (CHG‐IPA) versus 10% povidone‐iodine (PI), Outcome 3: Probable sepsis" data-id="CD013841-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_n/nCD013841-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_t/tCD013841-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: 2% chlorhexidine‐70% isopropyl (CHG‐IPA) versus 10% povidone‐iodine (PI), Outcome 3: Probable sepsis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/references#CD013841-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_n/nCD013841-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013841-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/urn:x-wiley:14651858:media:CD013841:CD013841-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: 2% chlorhexidine‐70% isopropyl (CHG‐IPA) versus 10% povidone‐iodine (PI), Outcome 4: All‐cause mortality" data-id="CD013841-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_n/nCD013841-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_t/tCD013841-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: 2% chlorhexidine‐70% isopropyl (CHG‐IPA) versus 10% povidone‐iodine (PI), Outcome 4: All‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/references#CD013841-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_n/nCD013841-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013841-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/urn:x-wiley:14651858:media:CD013841:CD013841-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: 2% chlorhexidine‐70% isopropyl (CHG‐IPA) versus 10% povidone‐iodine (PI), Outcome 5: Chemical burns" data-id="CD013841-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_n/nCD013841-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_t/tCD013841-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: 2% chlorhexidine‐70% isopropyl (CHG‐IPA) versus 10% povidone‐iodine (PI), Outcome 5: Chemical burns </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/references#CD013841-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_n/nCD013841-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013841-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/urn:x-wiley:14651858:media:CD013841:CD013841-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: 2% chlorhexidine‐70% isopropyl (CHG‐IPA) versus 10% povidone‐iodine (PI), Outcome 6: Catheter colonisation" data-id="CD013841-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_n/nCD013841-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_t/tCD013841-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: 2% chlorhexidine‐70% isopropyl (CHG‐IPA) versus 10% povidone‐iodine (PI), Outcome 6: Catheter colonisation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/references#CD013841-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_n/nCD013841-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013841-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/urn:x-wiley:14651858:media:CD013841:CD013841-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: 2% chlorhexidine‐70% isopropyl (CHG‐IPA) versus 10% povidone‐iodine (PI), Outcome 7: Thyroid dysfunction" data-id="CD013841-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_n/nCD013841-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_t/tCD013841-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: 2% chlorhexidine‐70% isopropyl (CHG‐IPA) versus 10% povidone‐iodine (PI), Outcome 7: Thyroid dysfunction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/references#CD013841-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_n/nCD013841-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013841-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/urn:x-wiley:14651858:media:CD013841:CD013841-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CHG‐IPA versus 2% chlorhexidine in aqueous (CHG‐A), Outcome 1: Proven CRBSI" data-id="CD013841-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_n/nCD013841-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_t/tCD013841-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: CHG‐IPA versus 2% chlorhexidine in aqueous (CHG‐A), Outcome 1: Proven CRBSI </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/references#CD013841-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_n/nCD013841-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013841-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/urn:x-wiley:14651858:media:CD013841:CD013841-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CHG‐IPA versus 2% chlorhexidine in aqueous (CHG‐A), Outcome 2: CLABSI" data-id="CD013841-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_n/nCD013841-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_t/tCD013841-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: CHG‐IPA versus 2% chlorhexidine in aqueous (CHG‐A), Outcome 2: CLABSI</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/references#CD013841-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_n/nCD013841-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013841-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/urn:x-wiley:14651858:media:CD013841:CD013841-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CHG‐IPA versus 2% chlorhexidine in aqueous (CHG‐A), Outcome 3: Chemical burns" data-id="CD013841-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_n/nCD013841-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_t/tCD013841-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: CHG‐IPA versus 2% chlorhexidine in aqueous (CHG‐A), Outcome 3: Chemical burns </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/references#CD013841-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_n/nCD013841-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013841-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/urn:x-wiley:14651858:media:CD013841:CD013841-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CHG‐IPA versus 2% chlorhexidine in aqueous (CHG‐A), Outcome 4: Catheter colonisation" data-id="CD013841-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_n/nCD013841-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_t/tCD013841-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: CHG‐IPA versus 2% chlorhexidine in aqueous (CHG‐A), Outcome 4: Catheter colonisation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/references#CD013841-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_n/nCD013841-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013841-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/urn:x-wiley:14651858:media:CD013841:CD013841-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CHG‐IPA versus 2% chlorhexidine in aqueous (CHG‐A), Outcome 5: Premature catheter removal" data-id="CD013841-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_n/nCD013841-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_t/tCD013841-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: CHG‐IPA versus 2% chlorhexidine in aqueous (CHG‐A), Outcome 5: Premature catheter removal </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/references#CD013841-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/media/CDSR/CD013841/image_n/nCD013841-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013841-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">CHG‐IPA versus PI for skin preparation during central‐catheter insertion in neonates</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CHG‐IPA versus PI for skin preparation during central‐catheter insertion in neonates</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> neonates that require central line </p> <p><b>Setting:</b> tertiary‐level NICUs in the USA and Ireland </p> <p><b>Intervention:</b> CHG‐IPA </p> <p><b>Comparison:</b> PI </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with PI</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with CHG‐IPA</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proven catheter‐related bloodstream infection (CRBSI) expressed by the authors of the individual trials as absolute rates assessed with: number of infants </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>44 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 1000</b><br/>(24 to 144) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.32</b><br/>(0.53 to 3.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>352<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>LOW <sup>a, b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Central line‐associated bloodstream infection (CLABSI) expressed using absolute rates of infants </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>42 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>42 per 1000</b> </p> <p>(3 to 628)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b> </p> <p>(0.07 to 15.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>VERY LOW <sup>c, d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The proportion of infants or catheters with exit‐site infection, either microbiologically or clinically documented </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trial assessed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Premature central line removal, defined as number of central venous catheters (CVCs) removed in the trial as deemed by the author as the source of infection </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trial assessed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chemical burns or contact dermatitis, measured using a scoring system or by clinical judgement as described by the trial author during or after the application of antiseptic solutions (dermatitis) assessed with: number of infants </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 per 1000</b><br/>(4 to 75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.04</b><br/>(0.24 to 4.48) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>352<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>VERY LOW <sup>c, e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality throughout the hospital admission of the participant (mortality) assessed with: number of infants </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>115 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>102 per 1000</b><br/>(53 to 194) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.88</b><br/>(0.46 to 1.68) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>304<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>LOW<sup>a, f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>CHG‐IPA:</b> 2% chlorhexidine in 70% isopropyl alcohol; <b>CRBSI</b> : catheter‐related bloodstream infection; <b>CVCs</b> : central venous catheters; <b>NICUs:</b> neonatal intensive care units; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Both trials had a high risk of performance bias. Certainty of evidence was downgraded by one level for serious limitation.<br/><sup>b</sup>The risk of CRBSI can possibly be halved with the use of CHG‐IPA. However, the increase in risk by 3.25 times was plausible. Certainty of evidence was downgraded by one level for imprecision.<br/><sup>c</sup>The included had a high risk of performance and detection biases. With very serious limitations, the certainty of evidence was downgraded by two levels.<br/><sup>d</sup>The risk of CLABSI with the use of CHG‐IPA or PI is the same. Certainty of evidence was downgraded by one level for imprecision.<br/><sup>e</sup>The risk of chemical burns reduced by 0.76 times with the use of CHG‐IPA but with a significant possibility of an increase in the risk of chemical burns by 4.5 times. Certainty of evidence was downgraded by one level for imprecision.<br/><sup>f</sup>The risk of death reduced by half with the use of CHG‐IPA. However, 1.7 times increase risk of death was plausible. Certainty of evidence was downgraded by one level for imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">CHG‐IPA versus PI for skin preparation during central‐catheter insertion in neonates</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/full#CD013841-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013841-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">CHG‐IPA versus CHG‐A for skin preparation during central‐catheter insertion in neonates</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CHG‐IPA versus CHG‐A for skin preparation during central‐catheter insertion in neonates</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> neonates that require central line </p> <p><b>Setting:</b> tertiary‐level NICUs in the UK </p> <p><b>Intervention:</b> CHG‐IPA </p> <p><b>Comparison:</b> CHG‐A </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with CHG‐A</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with CHG‐IPA</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proven catheter‐related bloodstream infection (CRBSI) expressed by the authors of the individual trial as absolute rates assessed with: number of infants </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>222 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>178 per 1000</b><br/>(416 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.80</b><br/>(0.34 to 1.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>LOW <sup>a, b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Central‐line associated bloodstream infection (CLABSI) expressed by the authors of the individual trial as absolute rates assessed with: number of infants </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>127 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>144 per 1000</b><br/>(43 to 486) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.14</b><br/>(0.34 to 3.84) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>LOW<sup>a, c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The proportion of infants or catheters with exit‐site infection, either microbiologically or clinically documented </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trial assessed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Premature central line removal, defined as number of central venous catheters (CVC) removed in the trial as deemed by the author as the source of infection (premature central line removal) assessed with: number of infants </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>101 per 1000</b><br/>(29 to 354) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.91</b><br/>(0.26 to 3.19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁⨁◯<br/>MODERATE<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chemical burns or contact dermatitis, measured using a scoring system or by clinical judgement as described by the trial author during or after the application of antiseptic solutions (dermatitis) assessed with: number of infants </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>259 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>254 per 1000</b><br/>(122 to 526) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.98</b><br/>(0.47 to 2.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁⨁◯<br/>MODERATE<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality throughout the hospital admission of the participant</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trial assessed this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CHG‐IPA:</b> 2% chlorhexidine in 70% isopropyl alcohol; <b>CHG‐A:</b> 2% chlorhexidine in aqueous solution; <b>CI:</b> confidence interval; <b>CRBSI:</b> catheter‐related bloodstream infection; <b>CVCs</b> : central venous catheters; <b>NICUs:</b> neonatal intensive care units; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>There was a high risk of attrition bias. The missing data were larger than the difference between events in the intervention and control groups. Certainty of evidence was downgraded by one level for serious limitation.<br/><sup>b</sup>There was a possible reduction in the risk of CRBSI by one‐third with the use of CHG‐IPA. However, the increase in risk by 1.9 times was plausible. Certainty of evidence was downgraded by one level for imprecision.<br/><sup>c</sup>There is an almost 0.7 times possible reduction in the risk of CLABSI with the use of CHG‐IPA. However, the increase in risk by 3.8 times is plausible. Certainty of evidence was downgraded by one level for imprecision.<br/><sup>d</sup>The risk of premature central catheter removal was reduced by 0.26 times with the use of CHG‐IPA but with a significant possibility of an increase in the risk of premature catheter removal by three times. Certainty of evidence was downgraded by one level for imprecision.<br/><sup>e</sup>The risk of chemical burns was reduced by half with the use of CHG‐IPA but with a significant possibility of an increase in the risk of chemical burns by two times. Certainty of evidence was downgraded by one level for imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">CHG‐IPA versus CHG‐A for skin preparation during central‐catheter insertion in neonates</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/full#CD013841-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013841-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">2% chlorhexidine‐70% isopropyl (CHG‐IPA) versus 10% povidone‐iodine (PI)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Proven catheter‐related blood stream infection (CRBSI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.53, 3.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Central‐line associated bloodstream infection (CLABSI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.07, 15.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Probable sepsis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.58, 2.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.46, 1.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Chemical burns <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.24, 4.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Catheter colonisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.34, 26.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Thyroid dysfunction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.00, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">2% chlorhexidine‐70% isopropyl (CHG‐IPA) versus 10% povidone‐iodine (PI)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/references#CD013841-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013841-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">CHG‐IPA versus 2% chlorhexidine in aqueous (CHG‐A)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Proven CRBSI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.34, 1.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 CLABSI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.34, 3.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Chemical burns <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.47, 2.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Catheter colonisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.09, 2.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Premature catheter removal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.26, 3.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">CHG‐IPA versus 2% chlorhexidine in aqueous (CHG‐A)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013841.pub2/references#CD013841-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013841.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013841-note-0014">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013841-note-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013841-note-0013">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013841-note-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD013841-note-0010">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD013841-note-0007">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD013841-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="th#CD013841-note-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013841-note-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013841-note-0006">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013841\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013841\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013841\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013841\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013841\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013841\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013841\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013841\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013841\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013841\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013841\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013841\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013841\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013841\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013841\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013841\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013841\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013841\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=p32VIvbS&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013841.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013841.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013841.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013841.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013841.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725871127"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013841.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725871130"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013841.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e85d0bbfc9371',t:'MTc0MDcyNTg3MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 